

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|------|---|---|------------------|---------|------------------|
| L1 | 606 | (544/330).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:53 |
| L2 | 1056 | (544/331).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:53 |
| L3 | 1293 | (514/275).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:53 |
| L5 | 21 | mark.inv. and Ledebor.inv. and pyrimidine | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:54 |
| L6 | 7 | Brian.inv. and Ledford.inv. and pyrimidine | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:54 |

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|------|--|---|------------------|---------|------------------|
| L1 | 606 | (544/330).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:53 |
| L2 | 1056 | (544/331).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:53 |
| L3 | 1293 | (514/275).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:53 |
| L5 | 21 | mark.inv. and Ledeboer.inv. and pyrimidine | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:54 |
| L6 | 7 | Brian.inv. and Ledford.inv. and pyrimidine | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2006/06/25 15:54 |

10/700,333

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | JAN 17 | Pre-1988 INPI data added to MARPAT |
| NEWS | 4 | FEB 21 | STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results |
| NEWS | 5 | FEB 22 | The IPC thesaurus added to additional patent databases on STN |
| NEWS | 6 | FEB 22 | Updates in EPFULL; IPC 8 enhancements added |
| NEWS | 7 | FEB 27 | New STN AnaVist pricing effective March 1, 2006 |
| NEWS | 8 | MAR 03 | Updates in PATDPA; addition of IPC 8 data without attributes |
| NEWS | 9 | MAR 22 | EMBASE is now updated on a daily basis |
| NEWS | 10 | APR 03 | New IPC 8 fields and IPC thesaurus added to PATDPAFULL |
| NEWS | 11 | APR 03 | Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL |
| NEWS | 12 | APR 04 | STN AnaVist \$500 visualization usage credit offered |
| NEWS | 13 | APR 12 | LINSPEC, learning database for INSPEC, reloaded and enhanced |
| NEWS | 14 | APR 12 | Improved structure highlighting in FQHIT and QHIT display in MARPAT |
| NEWS | 15 | APR 12 | Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected |
| NEWS | 16 | MAY 10 | CA/CAPLUS enhanced with 1900-1906 U.S. patent records |
| NEWS | 17 | MAY 11 | KOREAPAT updates resume |
| NEWS | 18 | MAY 19 | Derwent World Patents Index to be reloaded and enhanced |
| NEWS | 19 | MAY 30 | IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2 |
| NEWS | 20 | MAY 30 | The F-Term thesaurus is now available in CA/CAPLUS |
| NEWS | 21 | JUN 02 | The first reclassification of IPC codes now complete in INPADOC |
| | | | |
| NEWS EXPRESS | | | FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/ |
| | | | |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS IPC8 | | | For general information regarding STN implementation of IPC 8 |
| NEWS X25 | | | X.25 communication option no longer available after June 2006 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

10/700,333

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:32:19 ON 25 JUN 2006

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 15:32:28 ON 25 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2006 HIGHEST RN 889213-08-5
DICTIONARY FILE UPDATES: 23 JUN 2006 HIGHEST RN 889213-08-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107003333.str



chain nodes :

7 16 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
58 59 60 61 62

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

4-7 6-8 7-16 7-18 19-22 19-25 20-23 20-26 20-28 20-29 21-24 21-27 30-31
30-35 32-33 32-36 33-34 37-38 37-39 39-40 41-45 42-47 43-50 44-58 45-46
46-54 46-55 47-48 47-49 49-57 50-51 50-52 50-53 51-56 58-59 59-60 59-61
60-62

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

4-7 6-8 7-16 7-18 8-9 8-13 9-10 10-11 11-12 12-13 19-22 19-25 20-23
20-26 20-28 20-29 21-24 21-27 30-31 30-35 32-33 32-36 33-34 37-38 37-39
39-40 41-45 42-47 43-50 44-58 45-46 46-54 46-55 47-48 47-49 49-57 50-51
50-52 50-53 51-56 58-59 59-60 59-61 60-62

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 8 :

10/700,333

G1:C,N

G2:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 16:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS
22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:Atom 32:CLASS 33:CLASS 34:Atom 35:CLASS 36:CLASS 37:CLASS
38:CLASS 39:CLASS 40:Atom 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS
46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS
54:CLASS 55:Atom 56:Atom 57:Atom 58:CLASS 59:CLASS 60:CLASS 61:CLASS
62:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:32:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 237 TO ITERATE

100.0% PROCESSED 237 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3817 TO 5663

PROJECTED ANSWERS: 3 TO 163


L2 3 SEA SSS SAM L1

=> d scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Urea, N-[4-(2-chlorophenyl)-2-pyrimidinyl]-N'-[3-(trifluoromethyl)phenyl]-
(9CI)

MF C18 H12 Cl F3 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/700,333


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI)
MF C23 H17 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Thiophenecarboxamide, N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]-
(9CI)
MF C16 H10 F3 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss sam
SAMPLE SEARCH INITIATED 15:33:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 237 TO ITERATE

100.0% PROCESSED 237 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3817 TO 5663
PROJECTED ANSWERS: 3 TO 163

L3 3 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 15:33:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4932 TO ITERATE

100.0% PROCESSED 4932 ITERATIONS 120 ANSWERS

10/700,333

SEARCH TIME: 00.00.01

L4 120 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'CAPLUS' ENTERED AT 15:33:36 ON 25 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jun 2006 VOL 145 ISS 1

FILE LAST UPDATED: 23 Jun 2006 (20060623/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14

L5 25 L4

=> d 15 1-25 bib hitstr

L5 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1260610 CAPLUS

DN 144:22946

TI Preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases

IN Geuns-Meyer, Stephanie D.; Hodous, Brian L.; Chaffee, Stuart C.; Tempest, Paul A.; Olivieri, Philip R.; Johnson, Rebecca E.; Albrecht, Brian K.; Patel, Vinod F.; Cee, Victor J.; Kim, Joseph L.; Bellon, Steven; Zhu, Xiaotian; Cheng, Yuan; Xi, Ning; Romero, Karina; Nguyen, Hanh Nho; Deak, Holly L.

PA Amgen Inc., USA

SO PCT Int. Appl., 540 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|---|----------|-----------------|----------|
| PI | WO 2005113494 | A2 | 20051201 | WO 2005-US16346 | 20050509 |
| | WO 2005113494 | A3 | 20060316 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, | | | |

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

US 2006009453 A1 20060112 US 2005-126000 20050509
 PRAI US 2004-569193P P 20040507
 OS MARPAT 144:22946

IT **870232-85-2P**, N-(4-Chlorophenyl)-N'-[4-[[3-[2-[4-(4-methylpiperazin-1-yl)benzamido]pyrimidin-4-yl]pyridin-2-yl]oxy]phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(drug candidate; preparation of nitrogen-heteroaryl-containing protein
 kinase


modulators for use against cancer and other diseases)

RN 870232-85-2 CAPLUS


CN Benzamide, N-[4-[2-[4-[[[(4-chlorophenyl)amino]carbonyl]amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]-4-(4-methyl-1-piperazinyl)]- (9CI) (CA INDEX
 NAME)

PAGE 1-A





IT **870221-48-0P**, N-[4-(2-Chloropyridin-3-yl)pyrimidin-2-yl]-4-(4-methylpiperazin-1-yl)benzamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases)
 RN 870221-48-0 CAPLUS
 CN Benzamide, N-[4-(2-chloro-3-pyridinyl)-2-pyrimidinyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:395285 CAPLUS
 DN 142:430294
 TI Preparation of pyrimidine compounds as antistress agents
 IN Ohmoto, Kazuyuki; Kato, Masashi; Katsumata, Seishi; Manako, Junichiro
 PA Ono Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2005040135 | A1 | 20050506 | WO 2004-JP16056 | 20041022 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRAI JP 2003-365237 A 20031024
 OS MARPAT 142:430294
 IT **850924-15-1P 850924-16-2P 850924-19-5P**
850924-20-8P 850924-22-0P 850924-23-1P


850924-24-2P 850924-25-3P 850924-28-6P
 850924-29-7P 850924-32-2P 850924-33-3P
 850924-34-4P 850924-35-5P 850924-37-7P
 850924-38-8P 850924-40-2P 850924-41-3P
 850924-42-4P 850924-43-5P 850924-44-6P
 850924-45-7P 850924-46-8P 850924-47-9P
 850924-48-0P 850924-49-1P 850924-50-4P
 850924-51-5P 850924-52-6P 850924-53-7P
 850924-56-0P 850924-57-1P 850924-58-2P
 850924-59-3P 850924-60-6P 850924-61-7P
 850924-68-4P 850924-72-0P 850924-79-7P
 850924-80-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrimidine compds. for treatment of depression, asthma etc.)


RN 850924-15-1 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(4-methylphenyl)-2-pyrimidinyl]- (9CI) (CA
 INDEX NAME)




RN 850924-16-2 CAPLUS

CN Benzamide, N-[4-(4-methylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-19-5 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-[3-(trifluoromethyl)phenyl]-2-pyrimidinyl]-
 (9CI) (CA INDEX NAME)



RN 850924-20-8 CAPLUS


CN Benzamide, N-[4-[3-(trifluoromethyl)phenyl]-2-pyrimidinyl]- (9CI) (CA
 INDEX NAME)

10/700,333




RN 850924-22-0 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(4-cyanophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-23-1 CAPLUS

CN Benzamide, N-[4-(4-cyanophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-24-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(2-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-25-3 CAPLUS


CN Benzamide, N-[4-(2-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-28-6 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-(4-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/700,333




RN 850924-29-7 CAPLUS

CN Benzamide, N-[4-(4-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-32-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(2,4-difluorophenyl)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 850924-33-3 CAPLUS

CN Benzamide, N-[4-(2,4-difluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-34-4 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-(2-chlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-35-5 CAPLUS


CN Benzamide, N-[4-(2-chlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/700,333




RN 850924-37-7 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(4-chlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-38-8 CAPLUS

CN Benzamide, N-[4-(4-chlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-40-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(3-bromophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-41-3 CAPLUS


CN Benzamide, N-[4-(3-bromophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/700,333


RN 850924-42-4 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-43-5 CAPLUS

CN Benzamide, N-[4-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-44-6 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-45-7 CAPLUS


CN Benzamide, N-[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-46-8 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/700,333




RN 850924-47-9 CAPLUS

CN Benzamide, N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-48-0 CAPLUS

CN Benzamide, N-[4-(2,5-dimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-49-1 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-(2,5-dimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-50-4 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-[2,5-bis(1-methylethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/700,333




RN 850924-51-5 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-52-6 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(3-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-53-7 CAPLUS

CN Benzamide, N-[4-(3-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-56-0 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-(4-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/700,333


RN 850924-57-1 CAPLUS

CN Benzamide, N-[4-(4-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-58-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3-(acetylamino)phenyl]-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 850924-59-3 CAPLUS

CN Benzamide, N-[4-[3-(acetylamino)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-60-6 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RN 850924-61-7 CAPLUS


CN Benzamide, N-[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/700,333




RN 850924-68-4 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 850924-72-0 CAPLUS

CN Benzamide, N-(4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 850924-79-7 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-5-chloro- (9CI) (CA INDEX NAME)



RN 850924-80-0 CAPLUS

CN Urea, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RE.CNT 116 THERE ARE 116 CITED REFERENCES AVAILABLE FOR THIS RECORD


ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:324143 CAPLUS
 DN 142:392430
 TI A preparation of pyrimidine derivatives, useful as adenosine receptors ligands
 IN Chang, Lisa C. W.; Ijzerman, Adriaan P.; Brussee, Johannes
 PA Universiteit Leiden, Neth.
 SO PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2005033085 | A1 | 20050414 | WO 2004-NL683 | 20041001 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | GB 2003-23138 | A | 20031003 | | |
| OS | MARPAT 142:392430 | | | | |
| IT | 820961-58-8P 820961-72-6P 820961-73-7P 820961-74-8P 820961-75-9P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidine derivs. useful as adenosine receptors ligands) | | | | |
| RN | 820961-58-8 CAPLUS | | | | |
| CN | Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME) | | | | |




RN 820961-72-6 CAPLUS
 CN Cyclopropanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



10/700,333


RN 820961-73-7 CAPLUS

CN Cyclobutanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 820961-74-8 CAPLUS

CN Cyclopentanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-75-9 CAPLUS

CN Cyclohexanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:973406 CAPLUS

DN 142:114004

TI 2,4,6-Trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists

AU Chang, Lisa C. W.; Spanjersberg, Ronald F.; von Kuenzel, Jacobien K.; Mulder-Krieger, Thea; van den Hout, Gijs; Beukers, Margot W.; Brussee, Johannes; Ijzerman, Adriaan P.

CS Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, 2300 RA, Neth.

SO Journal of Medicinal Chemistry (2004), 47(26), 6529-6540
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

10/700,333

OS CASREACT 142:114004

IT 820961-58-8P 820961-59-9P 820961-60-2P

820961-61-3P 820961-62-4P 820961-63-5P

820961-72-6P 820961-73-7P 820961-74-8P


820961-75-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, polar surface area calcns., adenosine A receptor affinity, and structure-activity relationship of N-acyl(diphenyl)pyrimidinamines using heterocyclization and amidation with acid chlorides as the key steps)


RN 820961-58-8 CAPLUS

CN Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 820961-59-9 CAPLUS

CN Benzamide, 4-chloro-N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-60-2 CAPLUS


CN Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)-4-methoxy- (9CI) (CA INDEX NAME)



RN 820961-61-3 CAPLUS


CN Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)-4-methyl- (9CI) (CA INDEX NAME)

10/700,333




RN 820961-62-4 CAPLUS

CN Benzamide, 3,4-dichloro-N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 820961-63-5 CAPLUS

CN Benzamide, 3-chloro-N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-72-6 CAPLUS


CN Cyclopropanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-73-7 CAPLUS


CN Cyclobutanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

10/700,333




RN 820961-74-8 CAPLUS

CN Cyclopentanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-75-9 CAPLUS

CN Cyclohexanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:878265 CAPLUS

DN 141:366255

TI Preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors

IN Ding, Qiang; Sim, Tae-Bo; Zhang, Guobao; Adrian, Francisco; Gray, Nathanael S.; Schultz, Peter G.

PA IRM LLC, Bermuda

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2004089286 | A2 | 20041021 | WO 2004-US10083 | 20040402 |
| | WO 2004089286 | A3 | 20050421 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005014753 A1 20050120 US 2004-817328 20040401
 AU 2004227943 A1 20041021 AU 2004-227943 20040402
 CA 2521184 AA 20041021 CA 2004-2521184 20040402
 EP 1613595 A2 20060111 EP 2004-758738 20040402

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004009173 A 20060411 BR 2004-9173 20040402


PRAI US 2003-460838P P 20030404
 US 2004-817328 A 20040401
 WO 2004-US10083 W 20040402

OS MARPAT 141:366255

IT **778272-89-2P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)

RN 778272-89-2 CAPLUS

CN Benzamide, 3-chloro-N-[4-[2-[[4-(trifluoromethoxy)phenyl]amino]-4-pyridinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:292069 CAPLUS

DN 140:303694

TI Preparation of substituted pyrimidines for treating disorders mediated by the Cannabinoid-1 receptor

IN Kopka, Ihor E.; Li, Bing; Hagmann, William K.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 181 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----|--|------|----------|-----------------|----------|
| PI | WO 2004029204 | A2 | 20040408 | WO 2003-US30161 | 20030923 |
| | WO 2004029204 | A3 | 20040617 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, | | | | |

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG ..

| | | | | |
|---------------|----|----------|-----------------|----------|
| CA 2499497 | AA | 20040408 | CA 2003-2499497 | 20030923 |
| AU 2003275242 | A1 | 20040419 | AU 2003-275242 | 20030923 |
| EP 1546115 | A2 | 20050629 | EP 2003-759514 | 20030923 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

| | | | | |
|---------------|----|----------|----------------|----------|
| JP 2006510597 | T2 | 20060330 | JP 2004-539876 | 20030923 |
| US 2005245554 | A1 | 20051103 | US 2005-527561 | 20050311 |

PRAI US 2002-414144P P 20020927
WO 2003-US30161 W 20030923

OS MARPAT 140:303694


IT **676564-49-1P**, 2-(4-Fluorobenzamido)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine **676564-50-4P**, 2-(Cyclohexylcarbonylamino)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted pyrimidines for treating disorders mediated by the cannabinoid-1 receptor)


RN 676564-49-1 CAPLUS

CN Benzamide, N-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-pyrimidinyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 676564-50-4 CAPLUS

CN Cyclohexanecarboxamide, N-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN


AN 2004:205964 CAPLUS

DN 142:74474

TI Product class 12: pyrimidines

10/700,333

AU von Angerer, S.
CS Germany
SO Science of Synthesis (2004), 16, 379-572
CODEN: SSCYJ9
PB Georg Thieme Verlag
DT Journal; General Review
LA English
IT **54286-80-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrimidines via cyclization, ring transformation,
aromatization and substituent modification)
RN 54286-80-5 CAPLUS
CN Benzamide, N-(1,4-dihydro-4-oxo-6-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX
NAME)



RE.CNT 856 THERE ARE 856 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:551510 CAPLUS
DN 139:117434
TI Aminopyrimidines as adenosine receptor antagonists, processes for their
preparation and pharmaceutical compositions
IN Tsutsumi, Hideo; Yonishi, Satoshi; Akahane, Atsushi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 2003057689 | A1 | 20030717 | WO 2002-JP13796 | 20021227 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | | |
| | CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | | |
| | GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, | | | | |
| | LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, | | | | |
| | RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, | | | | |
| | US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, | | | | |
| | KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, | | | | |
| | FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, | | | | |
| | CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002358999 | A1 | 20030724 | AU 2002-358999 | 20021227 |
| | US 2005043315 | A1 | 20050224 | US 2004-498016 | 20040616 |
| PRAI | AU 2002-9796 | A | 20020102 | | |
| | AU 2002-1724 | A | 20020412 | | |
| | AU 2002-951403 | A | 20020916 | | |
| | WO 2002-JP13796 | W | 20021227 | | |
| IT | 560113-60-2P , N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4- | | | | |

phenyl-2-pyrimidinyl]cyclohexanecarboxamide **560113-62-4P**,
 N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]cyclopropanecarboxamide **560113-64-6P**,
 N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]benzamide **560113-65-7P**, 4-Fluoro-N-[5-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]benzamide **560113-66-8P**, 4-Chloro-N-[5-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]benzamide **560113-67-9P**,
 N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]-4-methoxybenzamide **560113-68-0P**, N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]-4-methylbenzamide **560113-69-1P**, N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]-4-(trifluoromethyl)benzamide **560113-70-4P**,
 N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]nicotinamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(A1 and A2a adenosine receptor ligand; preparation of aminopyrimidines as adenosine receptor antagonists)


RN 560113-60-2 CAPLUS

CN Cyclohexanecarboxamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 560113-62-4 CAPLUS


CN Cyclopropanecarboxamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 560113-64-6 CAPLUS


CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/700,333




RN 560113-65-7 CAPLUS

CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 560113-66-8 CAPLUS

CN Benzamide, 4-chloro-N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 560113-67-9 CAPLUS


CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 560113-68-0 CAPLUS


CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

10/700,333




RN 560113-69-1 CAPLUS

CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 560113-70-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:658746 CAPLUS

DN 137:185833

TI Preparation of novel heterocyclic urea compounds, particularly
N-hydroxy-2-[N-substituted-N-[(2-substituted-pyrrolidin-1-yl)carbonyl]amino]acetamides, with activity as peptide deformylase
inhibitors, their compositions and methods of use as antimicrobials

IN Jacobs, Jeffrey W.; Patel, Dinesh; Lewis, Jason; Ni, Zhi-Jie

PA Vicuron Pharmaceuticals Inc., USA

SO U.S. Pat. Appl. Publ., 40 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | US 2002119962 | A1 | 20020829 | US 2000-738376 | 20001213 |
| | US 6852752 | B2 | 20050208 | | |
| PRAI | US 1999-266329P | P | 19991217 | | |

10/700,333

OS MARPAT 137:185833

IT **345890-40-6P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heterocyclic urea hydroxamates as peptide deformylase inhibitors for use as antimicrobials)

RN 345890-40-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(2-cyclopentylethyl)-N1-[2-(hydroxyamino)-2-oxoethyl]-N2-(4-phenyl-2-pyrimidinyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:639736 CAPLUS

DN 138:201537

TI N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity

AU Hackbarth, Corinne J.; Chen, Dawn Z.; Lewis, Jason G.; Clark, Kirk; Mangold, James B.; Cramer, Jeffrey A.; Margolis, Peter S.; Wang, Wen; Koehn, Jim; Wu, Charlotte; Lopez, S.; Withers, George, III; Gu, Helen; Dunn, Elina; Kulathila, R.; Pan, Shi-Hao; Porter, Wilma L.; Jacobs, Jeff; Trias, Joaquim; Patel, Dinesh V.; Weidmann, Beat; White, Richard J.; Yuan, Zhengyu

CS Versicor, Inc., Fremont, CA, 94555, USA

SO Antimicrobial Agents and Chemotherapy (2002), 46(9), 2752-2764
CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

IT **345890-40-6P**


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(alkyl urea hydroxamic acids as new class of peptide deformylase inhibitors with antibacterial activity)

RN 345890-40-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(2-cyclopentylethyl)-N1-[2-(hydroxyamino)-2-oxoethyl]-N2-(4-phenyl-2-pyrimidinyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:453006 CAPLUS
DN 135:61229
TI Novel heterocyclic urea compounds, particularly N-hydroxy-2-[N-substituted-N-[(2-substituted-pyrrolidin-1-yl)carbonyl]amino]acetamides, with activity as peptide deformylase inhibitors, and their compositions, methods of use as antimicrobials, and preparation
IN Ni, Zhi-jie; Jacobs, Jeffrey W.; Patel, Dinesh V.; Lewis, Jason
PA Versicor, Inc., USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------|--|----------|-----------------|----------|
| PI WO 2001044178 | A1 | 20010621 | WO 2000-US34126 | 20001213 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI US 1999-266329P | P | 19991217 | | |
| US 1999-466402 | A1 | 19991217 | | |

OS MARPAT 135:61229

IT **345890-40-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic urea hydroxamates as peptide deformylase inhibitors for use as antimicrobials)

RN 345890-40-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(2-cyclopentylethyl)-N1-[2-(hydroxyamino)-2-oxoethyl]-N2-(4-phenyl-2-pyrimidinyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:78219 CAPLUS
DN 134:141718
TI Pyrimidine derivative inhibitors of viral helicase
IN Hale, Michael; Maltais, Francois; Baker, Christopher; Janetka, James;
Moon, Young Choon; Saunders, Jeffrey
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2001007027 | A2 | 20010201 | WO 2000-US19650 | 20000719 |
| | WO 2001007027 | A3 | 20010809 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

CN Urea, N-[6-(4-bromophenyl)-5-cyano-1,4-dihydro-4-oxo-2-pyrimidinyl]-N'-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:227649 CAPLUS
 DN 132:265206
 TI Preparation of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease
 IN Watanabe, Kazutoshi; Ando, Ryoichi; Saito, Ken-ichi; Kawamoto, Rie; Shoda, Aya
 PA Mitsubishi Chemical Corporation, Japan
 SO PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|----------|
| PI | WO 2000018758 | A1 | 20000406 | WO 1999-JP5224 | 19990924 |
| | W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2345065 | AA | 20000406 | CA 1999-2345065 | 19990924 |
| | AU 9957599 | A1 | 20000417 | AU 1999-57599 | 19990924 |
| | EP 1115721 | A1 | 20010718 | EP 1999-944815 | 19990924 |
| | EP 1115721 | B1 | 20031210 | | |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| | JP 2002525366 | T2 | 20020813 | JP 2000-572218 | 19990924 |
| | AT 256123 | E | 20031215 | AT 1999-944815 | 19990924 |
| | PT 1115721 | T | 20040430 | PT 1999-944815 | 19990924 |
| | ES 2214045 | T3 | 20040901 | ES 1999-944815 | 19990924 |
| PRAI | JP 1998-271277 | A | 19980925 | | |
| | JP 1998-305266 | A | 19981027 | | |
| | WO 1999-JP5224 | W | 19990924 | | |


OS MARPAT 132:265206

IT **263244-10-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease)


RN 263244-10-6 CAPLUS

CN Benzamide, N-[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:446847 CAPLUS
DN 129:135874
TI Strong Dimerization of Ureidopyrimidones via Quadruple Hydrogen Bonding
AU Beijer, Felix H.; Sijbesma, Rint P.; Kooijman, Huub; Spek, Anthony L.;
Meijer, E. W.
CS Laboratory of Organic Chemistry, Eindhoven University of Technology,
Eindhoven, 5600 MB, Neth.
SO Journal of the American Chemical Society (1998), 120(27), 6761-6769
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
IT **210709-60-7P 210709-61-8P 210709-62-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(hydrogen bond dimer formation for ureidopyrimidones via quadruple
hydrogen bonding)
RN 210709-60-7 CAPLUS
CN Urea, N-[1,4-dihydro-4-oxo-6-[3,4,5-tris(dodecyloxy)phenyl]-2-pyrimidinyl]-
N'-phenyl- (9CI) (CA INDEX NAME)




RN 210709-61-8 CAPLUS
CN Urea, N-[1,4-dihydro-4-oxo-6-[3,4,5-tris(dodecyloxy)phenyl]-2-pyrimidinyl]-
N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 210709-62-9 CAPLUS

CN Urea, N-[4-(diethylamino)phenyl]-N'-[1,4-dihydro-4-oxo-6-[3,4,5-tris(dodecyloxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:394334 CAPLUS

DN 129:67791

TI Preparation of 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidines and related compounds as drugs

IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.

PA Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.

SO PCT Int. Appl., 232 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 9824782 | A2 | 19980611 | WO 1997-US22390 | 19971204 |
| | WO 9824782 | A3 | 19980827 | | |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | ZA 9710727 | A | 19980612 | ZA 1997-10727 | 19971128 |
| | CA 2274063 | AA | 19980611 | CA 1997-2274063 | 19971204 |
| | AU 9860120 | A1 | 19980629 | AU 1998-60120 | 19971204 |
| | AU 733877 | B2 | 20010531 | | |
| | EP 948497 | A2 | 19991013 | EP 1997-954778 | 19971204 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | BR 9713850 | A | 20000229 | BR 1997-13850 | 19971204 |
| | CN 1246858 | A | 20000308 | CN 1997-181563 | 19971204 |
| | NZ 335997 | A | 20010831 | NZ 1997-335997 | 19971204 |

JP 2002514195 T2 20020514 JP 1998-525850 19971204
 TW 520362 B 20030211 TW 1997-86118244 19971204
 EP 1314731 A2 20030528 EP 2002-27704 19971204
 EP 1314731 A3 20040102
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, LT, LV, FI, RO, MK, AL
 EP 1314732 A2 20030528 EP 2002-27705 19971204
 EP 1314732 A3 20040102
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, AL
 ZA 9710911 A 19980605 ZA 1997-10911 19971205
 MX 9905168 A 20000228 MX 1999-5168 19990603
 US 6410729 B1 20020625 US 2000-598740 20000621
 US 2003069425 A1 20030410 US 2002-117552 20020403
 US 6610698 B2 20030826
 PRAI US 1996-32128P P 19961205
 US 1997-50950P P 19970613
 US 1997-976054 A 19971121
 EP 1997-954778 A3 19971204
 US 1997-984774 B1 19971204
 WO 1997-US22390 W 19971204
 US 2000-598740 A3 20000621
 OS MARPAT 129:67791
 IT **208936-03-2P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-substituted (fluorophenyl)(pyridyl)pyrimidines and related
 compds. as drugs)
 RN 208936-03-2 CAPLUS
 CN Benzamide, N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-2-pyrimidinyl]- (9CI)
 (CA INDEX NAME)




L5 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:611675 CAPLUS
 DN 123:285884
 TI Synthesis and reactions of 2-amino-4-aryl-6-(2'-methoxynaphthyl)pyrimidines
 AU Essawy, S. A.; El-Sawy, A. A.; Issac, Y. A.; Ghany, A. M. Abdel
 CS Faculty Science, Benha University, Benha, Egypt
 SO Egyptian Journal of Chemistry (1994), 37(4), 423-31
 CODEN: EGJCA3; ISSN: 0367-0422
 PB National Information and Documentation Centre
 DT Journal
 LA English
 IT **169318-79-0P 169318-82-5P 169318-83-6P**
169318-98-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reactions of amino(aryl)(methoxynaphthalenyl)pyrimidines)

10/700,333


RN 169318-79-0 CAPLUS

CN Urea, N-[4-(4-chlorophenyl)-6-(2-methoxy-1-naphthalenyl)-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 169318-82-5 CAPLUS

CN Benzamide, N-[4-(4-chlorophenyl)-6-(2-methoxy-1-naphthalenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 169318-83-6 CAPLUS

CN Benzamide, N-[4-(2-methoxy-1-naphthalenyl)-6-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 169318-98-3 CAPLUS


CN Urea, N-[4-(2-methoxy-1-naphthalenyl)-6-(4-methoxyphenyl)-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:435528 CAPLUS
 DN 121:35528
 TI Synthesis and biological activity of some 4-(p-chlorophenyl)-6-(o-hydroxyphenyl)-2-aminopyrimidine derivatives: Part 1
 AU Abdel-Halim, A. M.; Tawfik, A. M.; Ibrahim, S. S.; El-Kazak, A. M.
 CS Fac. Educ., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Heterocyclic Chemistry (1994), 3(3), 165-70
 CODEN: IJCHEI; ISSN: 0971-1627
 DT Journal
 LA English
 IT **155733-31-6P 155733-32-7P 155733-33-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 155733-31-6 CAPLUS
 CN Benzamide, 4-chloro-N-[4-(4-chlorophenyl)-6-(2-hydroxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 155733-32-7 CAPLUS
 CN Benzamide, N-[4-(4-chlorophenyl)-6-(2-hydroxyphenyl)-2-pyrimidinyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 155733-33-8 CAPLUS

10/700,333

CN Benzamide, N-[4-(4-chlorophenyl)-6-(2-hydroxyphenyl)-2-pyrimidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:38868 CAPLUS

DN 118:38868

TI A facile one-step conversion of β -benzoylacrylic acids into some interesting heterocycles and study of their microbiological activity

AU El-Kafrawy, A. F.; El-Bassiouny, F. A.; Sayed, M. A.; El-Hashash, M. A.

CS Fac. Sci., Ain Shams Univ., Cairo, Egypt

SO Journal of the Chemical Society of Pakistan (1992), 14(1), 59-66

CODEN: JCSPDF; ISSN: 0253-5106

DT Journal

LA English


OS CASREACT 118:38868

IT **145274-36-8P 145274-37-9P 145274-38-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 145274-36-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(benzoylamino)-6-(4-phenoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 145274-37-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(benzoylamino)-6-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




10/700,333


RN 145274-38-0 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-[(2-chlorobenzoyl)amino]-6-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:407157 CAPLUS
DN 107:7157
TI Heterocyclic rearrangements. Synthesis of 1,2,4-oxadiazolo[2,3-a]pyrimidinium systems and their ring opening into pyrimidine N-oxides
AU Buscemi, Silvestre; Macaluso, Gabriella; Frenna, Vincenzo; Vivona, Nicolo
CS Ist. Chim. Org., Univ. Palermo, Palermo, 90123, Italy
SO Journal of Heterocyclic Chemistry (1986), 23(4), 1175-7
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 107:7157
IT **108656-01-5P 108656-08-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 108656-01-5 CAPLUS
CN Benzamide, N-(4-methyl-1-oxido-6-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 108656-08-2 CAPLUS
CN Benzamide, N-(6-methyl-1-oxido-4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1982:85504 CAPLUS
 DN 96:85504
 TI Alkylation and acylation of 2-aminopyrimidine N-oxides
 AU Sedova, V. F.; Mustafina, T. Yu.; Mamaev, V. P.
 CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1981), (11), 1515-22
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 OS CASREACT 96:85504
 IT **80830-47-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, with perchloric acid)
 RN 80830-47-3 CAPLUS
 CN Benzamide, N-(1-oxido-4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



IT **80830-59-7P 80830-65-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 80830-59-7 CAPLUS
 CN Urea, N-(1-oxido-4-phenyl-2-pyrimidinyl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 80830-65-5 CAPLUS
 CN Urea, N-(4-chlorophenyl)-N'-(1-oxido-4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN.
 AN 1981:30763 CAPLUS
 DN 94:30763
 TI Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and -1H-1,2,4-triazoles
 IN Heeres, Jan; Mostmans, Joseph H.
 PA Janssen Pharmaceutica N. V., Belg.
 SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 918,257, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 4218458 | A | 19800819 | US 1979-20287 | 19790314 |
| | EP 6712 | A1 | 19800109 | EP 1979-301130 | 19790613 |
| | EP 6712 | B1 | 19831130 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE | | | | |
| | AT 5479 | E | 19831215 | AT 1979-301130 | 19790613 |
| | JP 55011579 | A2 | 19800126 | JP 1979-77630 | 19790621 |
| | JP 63044752 | B4 | 19880906 | | |
| | US 4313953 | A | 19820202 | US 1980-134384 | 19800327 |
| | US 4533550 | A | 19850806 | US 1981-558331 | 19810827 |
| PRAI | US 1978-918257 | A2 | 19780623 | | |
| | US 1979-20287 | | 19790314 | | |
| | EP 1979-301130 | A | 19790613 | | |
| | US 1980-134384 | A3 | 19800327 | | |

OS CASREACT 94:30763; MARPAT 94:30763


IT **74740-41-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of fungicidal and bactericidal)

RN 74740-41-3, CAPLUS

CN Benzamide, N-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-2-pyrimidinyl]-4-fluoro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10/700,333


IT **74740-40-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, fungicidal and bactericidal)

RN 74740-40-2 CAPLUS

CN Benzamide, N-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-2-pyrimidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1980:514502 CAPLUS

DN 93:114502

TI Pesticidal heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and -1H-1,2,4-triazoles

IN Heeres, Jan; Mostmans, Joseph

PA Janssen Pharmaceutica N. V., Belg.

SO Eur. Pat. Appl., 89 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 6712 | A1 | 19800109 | EP 1979-301130 | 19790613 |
| | EP 6712 | B1 | 19831130 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE | | | | |
| | US 4218458 | A | 19800819 | US 1979-20287 | 19790314 |
| | AT 5479 | E | 19831215 | AT 1979-301130 | 19790613 |
| PRAI | US 1978-918257 | | 19780623 | | |
| | US 1979-20287 | | 19790314 | | |
| | EP 1979-301130 | A | 19790613 | | |


IT **74740-40-2P 74740-41-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 74740-40-2 CAPLUS

CN Benzamide, N-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-2-pyrimidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 74740-41-3 CAPLUS

CN Benzamide, N-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-2-pyrimidinyl]-4-fluoro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1977:155600 CAPLUS

DN 86:155600

TI Synthesis of a new ring system: 1,2,4-oxidiazole[2,3a]pyrimidin-4-one

AU Vivona, Nicolo; Cusmano, Giuseppe

CS Fac. Sci., Univ. Palermo, Palermo, Italy

SO Heterocycles (1977), 6(2), 107-10

CODEN: HTCYAM; ISSN: 0385-5414

DT Journal

LA English

10/700,333


OS CASREACT 86:155600

IT **54286-80-5P**

RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, in hydrogenation of diphenyloxadiazolopyrimidinone)

RN 54286-80-5 CAPLUS

CN Benzamide, N-(1,4-dihydro-4-oxo-6-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:43328 CAPLUS

DN 82:43328

TI Heterocyclic transformations by hydrogenolysis. Pyrimidine derivatives from 1,2,4-oxadiazole derivatives

AU Ruccia, M.; Vivona, N.; Cusmano, G.

CS Ist. Chim. Org., Fac. Sci., Palermo, Italy

SO Journal of Heterocyclic Chemistry (1974), 11(5), 829-30

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal


LA English

IT **54286-80-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 54286-80-5 CAPLUS

CN Benzamide, N-(1,4-dihydro-4-oxo-6-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1955:23952 CAPLUS

DN 49:23952

OREF 49:4658f-i,4659a-c

TI Guanidine and biguanidine derivatives. II. Synthesis of new derivatives of o-phenylenebiguanide, 2-aminobenzimidazole, ω-phenylbiguanide, guanilphenylurea, and guanilurea

AU Ridi, Mario; Checchi, Silvio


CS Univ. Florence

SO Annali di Chimica (Rome, Italy) (1954), 44, 28-38

CODEN: ANCRAI; ISSN: 0003-4592

10/700,333

DT Journal
LA Unavailable
IT **859734-98-8**, Urea, 1-(3,4-dihydro-4-oxo-6-phenyl-2-(1H)-
pyrimidinylidene)-3-phenyl-
(preparation of)
RN 859734-98-8 CAPLUS
CN Urea, 1-(3,4-dihydro-4-oxo-6-phenyl-2-(1H)-pyrimidinylidene)-3-phenyl-
(5CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION



FULL ESTIMATED COST

88.21

255.80

STN INTERNATIONAL LOGOFF AT 15:34:09 ON 25 JUN 2006

10/700,333



chain nodes :

7 14 17 18

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

1-17 3-7 5-10 14-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

3-7 14-18

exact bonds :

1-17 5-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

isolated ring systems :

containing 1 : 8 :



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:CLASS 15:CLASS 17:CLASS 18:CLASS

6.25-06

=>

Uploading C:\Program Files\Stnexp\Queries\10639784.str



chain nodes :

7 14

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

3-7 5-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

3-7

exact bonds :

5-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

isolated ring systems :

containing 1 : 8 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s ll sss sam
 SAMPLE SEARCH INITIATED 19:41:35 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 1319 TO ITERATE



100.0% PROCESSED 1319 ITERATIONS 50 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 24202 TO 28558
 PROJECTED ANSWERS: 5859 TO 8099

L2 50 SEA SSS SAM L1

=> =>

Uploading C:\Program Files\Stnexp\Queries\10639784 (a).str



chain nodes :
 7 14 17

ring nodes :
 1 2 3 4 5 6 8 9 10 11 12 13
 chain bonds :
 1-17 3-7 5-10
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
 exact/norm bonds :
 3-7
 exact bonds :
 1-17 5-10
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
 isolated ring systems :
 containing 1 : 8 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 17:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam

SAMPLE SEARCH INITIATED 19:43:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1319 TO ITERATE

100.0% PROCESSED 1319 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)


SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 24202 TO 28558
 PROJECTED ANSWERS: 2671 TO 4249

L4 50 SEA SSS SAM L3

=> =>

Uploading C:\Program Files\Stnexp\Queries\10639784 (b).str



chain nodes :

7 14 17 18

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

1-17 3-7 5-10 14-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

3-7 14-18

exact bonds :

1-17 5-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

isolated ring systems :

containing 1 : 8 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 17:CLASS 18:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 19:44:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1319 TO ITERATE

100.0% PROCESSED 1319 ITERATIONS

27 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 24202 TO 28558

PROJECTED ANSWERS: 229 TO 851

L6 27 SEA SSS SAM L5

=> => s 15 sss ful

FULL SEARCH INITIATED 19:45:00 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 26604 TO ITERATE

100.0% PROCESSED 26604 ITERATIONS

446 ANSWERS

SEARCH TIME: 00.00.01

L7 446 SEA SSS FUL L5

=> => s 17

L8 29 L7


=> d 18 1-29 bib,ab,hitstr

L8 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:1075803 CAPLUS
 DN 143:367317
 TI Preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides as inhibitors
 of histone deacetylase
 IN Delorme, Daniel; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana;
 Raepfel, Stephane; Frechette, Sylvie; Bouchain, Giliane; Zhou, Zhihong;
 Paquin, Isabelle; Gaudette, Frederic; Isakovic, Ljubomir
 PA Methylgene Inc., Can.
 SO PCT Int. Appl., 245 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2005092899 | A1 | 20051006 | WO 2005-CA454 | 20050329 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 2004-556828P | P | 20040326 | | |
| | US 2005-90713 | A | 20050325 | | |
| | WO 2005-IB802 | A | 20050325 | | |

AB The invention relates to N-(2-amino and 2-hydroxy)phenyl carboxamides (2-TC6H4NHC(O)(CH:CH)qAr-X-Cy (I); variables defined below; e.g. (E)-N-(2-Aminophenyl)-3-[4-[[2-(hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylamide (shown as II)) useful for inhibiting histone deacetylase (HDAC) enzymic activity. The invention also provides a method for inhibiting histone deacetylase in a cell using said compds. as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compns. comprising the HDAC inhibiting compds. and a pharmaceutically acceptable carrier. For I: Cy is aryl, heteroaryl, cycloalkyl, or heterocyclyl, each of which is (un)substituted and each of which is optionally fused to ≥1 aryl or heteroaryl rings, or to ≥1 saturated or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings is (un)substituted; X = a chemical bond, L, W-L, L-W, and L-W-L, wherein W, at each occurrence, is S, O, C=O, or N(R9), where R9 = H, alkyl, hydroxyalkyl, and tert-butoxycarbonyl; and L = C1-C4 alkylene; Ar is arylene or heteroarylene, each of which is (un)substituted; q = 0-1; and T is NH2 or OH, provided that when Cy is naphthyl, X is -CH2-, Ar is Ph, and q = 0-1, T is not OH. Although the methods of preparation are not claimed, 215 example preps. and/or characterization data are included. For example, II was prepared in 6 steps (59, 83, 97, 79, 96 and 80 % yields) starting from (E)-4-formylcinnamic acid and involving intermediates Me (E)-3-(4-formylphenyl)acrylate, Me (E)-3-[4-[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylate, Me (E)-3-[4-[[[2-[(tert-butyl)dimethylsilyl]oxy]ethyl][2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylate, (E)-3-[4-[[[2-[(tert-butyl)dimethylsilyl]oxy]ethyl][2-(1H-indol-3-

yl)ethyl]amino]methyl]phenyl]acrylic acid and (E)-N-(2-aminophenyl)-3-[4-
 [[[2-[(tert-butyldimethylsilyl)oxy]ethyl][2-(1H-indol-3-
 yl)ethyl]amino]methyl]phenyl]acrylamide.
 IT 866000-03-5P, 4-[[[4-(3-Acetylphenyl)pyrimidin-2-yl]amino]methyl]-
 N-(2-aminophenyl)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides
 as inhibitors of histone deacetylase)
 RN 866000-03-5 CAPLUS
 CN Benzamide, 4-[[[4-(3-acetylphenyl)-2-pyrimidinyl]amino]methyl]-N-(2-
 aminophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:823509 CAPLUS
 DN 143:229572
 TI Preparation of benzamides for treating a disorder mediated by
 inappropriate ROCK-1 activity
 IN Drewry, David Kendall; Jung, David Kendall; Linn, James Andrew; Hunter,
 Robert Neil, III; Lee, Dennis; Stavenger, Robert A.; Sehon, Clark
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2005074643 | A2 | 20050818 | WO 2005-US3479 | 20050128 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI US 2004-540621P P 20040130

OS MARPAT 143:229572

AB The title compds. I [R1 = H, alkyl or as indicated by the dotted line is
 fused to the Ph forming a 5-6 membered ring, optionally containing a double
 bond; n = 0-4; R2 = (un)substituted aryl, etc.; or when n = 0 then NR1R2 =
 5-6 membered monocyclic heterocyclic ring or 9-10 membered bicyclic
 heterocyclic ring; X = indazolyl, pyrazolyl, (un)substituted pyridyl,
 pyrimidinyl], useful for treating disorders mediated by inappropriate
 ROCK-1 activity, were prepared E.g., a 3-step synthesis of II, starting
 from Me 4-bromobenzoate and 4-pyridylboronic acid, was given. All
 exemplified compds. I showed inhibitory activity vs. Rock-1 with a pIC50
 of 5.0 or greater. The pharmaceutical composition comprising the compound I is
 disclosed.


IT 862723-00-0P 862723-07-7P 862723-08-8P
 862723-09-9P 862723-10-2P 862723-11-3P
 862723-12-4P 862723-13-5P 862723-14-6P
 862723-15-7P 862723-16-8P 862723-17-9P
 862723-18-0P 862723-19-1P 862723-20-4P
 862723-21-5P 862723-22-6P 862723-23-7P
 862723-24-8P 862723-26-0P 862723-27-1P
 862723-28-2P 862723-30-6P 862723-32-8P
 862723-33-9P 862723-34-0P 862723-35-1P
 862723-36-2P 862723-38-4P 862723-39-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamides for treating a disorder mediated by inappropriate
 ROCK-1 activity)


RN 862723-00-0 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-methoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 862723-07-7 CAPLUS

CN Benzamide, 4-[(2-amino-4-pyrimidinyl)-N-[(4-methoxyphenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 862723-08-8 CAPLUS

CN Benzamide, 4-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 862723-09-9 CAPLUS

CN Benzamide, 4-[(2-amino-4-pyrimidinyl)-N-[(2-chlorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 862723-10-2 CAPLUS

CN Benzamide, 4-[(2-amino-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 862723-11-3 CAPLUS

CN Benzamide, 4-((2-amino-4-pyrimidin-5-yl)phenyl)-N-((4-chlorophenyl)methyl)- (9CI)
(CA INDEX NAME)




RN 862723-12-4 CAPLUS

CN Benzamide, 4-((2-amino-4-pyrimidin-5-yl)phenyl)-N-((2-fluorophenyl)methyl)- (9CI)
(CA INDEX NAME)




RN 862723-13-5 CAPLUS

CN Benzamide, 4-((2-amino-4-pyrimidin-5-yl)phenyl)-N-((2-methoxyphenyl)methyl)- (9CI)
(CA INDEX NAME)




RN 862723-14-6 CAPLUS

CN Benzamide, 4-((2-amino-4-pyrimidin-5-yl)phenyl)-N-((2-methylphenyl)methyl)- (9CI)
(CA INDEX NAME)



RN 862723-15-7 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-(2,3-dihydro-1H-inden-1-yl)- (9CI)
(CA INDEX NAME)



RN 862723-16-8 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862723-17-9 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 862723-18-0 CAPLUS

CN Carbamic acid, [[3-[[[4-(2-amino-4-pyrimidinyl)benzoyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 862723-19-1 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 862723-20-4 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 862723-21-5 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 862723-22-6 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 862723-23-7 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862723-24-8 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862723-26-0 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 862723-27-1 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[[3-(difluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 862723-28-2 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-(1-methyl-1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 862723-30-6 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3,5-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 862723-32-8 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-([1,1'-biphenyl]-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 862723-33-9 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862723-34-0 CAPLUS

CN Carbamic acid, [3-[1-[[4-(2-amino-4-pyrimidinyl)benzoyl]amino]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 862723-35-1 CAPLUS


CN Benzamide, N-[(2-aminophenyl)methyl]-4-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 862723-36-2 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862723-38-4 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862723-39-5 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylpropyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



IT 216959-98-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of benzamides for treating a disorder mediated by inappropriate
ROCK-1 activity)
RN 216959-98-7 CAPLUS
CN Benzoic acid, 4-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:638854 CAPLUS
 DN 143:153392
 TI Preparation of aryl pyrimidines as protein kinase C inhibitors
 IN Fleming, Paul E.; Shi, Zhan; Chen, Shaowu; Schmidt, Jane F.; Reader, John C.; Hone, Neal D.; Ciavarri, Jeffrey P.
 PA Millennium Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 177 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----|--|------|----------|-----------------|----------|
| PI | WO 2005066139 | A2 | 20050721 | WO 2005-US663 | 20050110 |
| | WO 2005066139 | A3 | 20051013 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI US 2004-534898P P 20040108

OS MARPAT 143:153392


AB Title compds. I [R1 and R2 independently = H, alkyl, cycloalkyl; R3 = H or F; R4 = H, F, C(O)R, etc., or R3 and R4 together = carbonyl; R = H, alkyl, cycloalkyl; ring A is optionally substituted with R5; R5 = halo, CN, aliphatic, etc.; Cyl = (un)substituted 6-membered aryl or heteroaryl, 5-membered heteroaryl; Q = bond, CH2, CO; Cy2 = (un)substituted aryl, heteroaryl, heterocycle] and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase C (PKC) inhibitors. Thus, e.g., II was prepared by coupling of (3-([3-(2-chloro-pyrimidin-4-yl)-benzyl]-ethyl-amino)-propyl)carbamic acid tert-Bu ester (preparation given) with tyramine and subsequent deprotection. The inhibitory activity of I against PKC-theta isoform was evaluated in an enzyme assay following the emission of europium cryptate (at 615 nm) and streptavidin-allophycocyanin (at 665 nm) and it was revealed that selected compds. of the invention display IC50 values less than 100 nM. I as PKC inhibitor should prove useful in the treatment of inflammatory diseases such as, but not limited to, rheumatoid arthritis, asthma, and multiple sclerosis. Pharmaceutical compns. comprising I are disclosed.

IT 859514-46-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of aryl pyrimidines as protein kinase C inhibitors)

RN 859514-46-8 CAPLUS

CN Benzoic acid, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 859514-47-9P 859514-48-0P 859514-49-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl pyrimidines as protein kinase C inhibitors)


RN 859514-47-9 CAPLUS

CN Benzamide, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-N-(3-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 859514-48-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 859514-49-1 CAPLUS

CN Benzamide, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-N-(2-piperidinylmethyl)- (9CI) (CA INDEX NAME)




IT 859516-87-3P 859517-06-9P 859517-17-2P,
1-(3-[2-[[2-(4-Methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl)ethanone
859517-31-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of aryl pyrimidines as protein kinase C inhibitors)


RN 859516-87-3 CAPLUS

CN Benzoic acid, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 859517-06-9 CAPLUS

CN Benzaldehyde, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 859517-17-2 CAPLUS

CN Ethanone, 1-[3-[2-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859517-31-0 CAPLUS

CN Ethanone, 1-[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:878265 CAPLUS
 DN 141:366255
 TI Preparation of substituted pyrimidinamines and triazinamines as protein
 kinase inhibitors
 IN Ding, Qiang; Sim, Tae-Bo; Zhang, Guobao; Adrian, Francisco; Gray,
 Nathanael S.; Schultz, Peter G.
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2004089286 | A2 | 20041021 | WO 2004-US10083 | 20040402 |
| | WO 2004089286 | A3 | 20050421 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2005014753 | A1 | 20050120 | US 2004-817328 | 20040401 |
| | CA 2521184 | AA | 20041021 | CA 2004-2521184 | 20040402 |
| PRAI | US 2003-460838P | P | 20030404 | | |
| | US 2004-817328 | A | 20040401 | | |
| | WO 2004-US10083 | W | 20040402 | | |

OS MARPAT 141:366255

AB The title compds. [I; X1, X2 = N, CR4 (wherein R4 = H, alkyl); L = a bond, O, NR5 (R5 = H, alkyl); R1 = X3NR6R7, X3OR7, X3R7 (X3 = a bond, alkylene; R6 = H, alkyl; R7 = aryl, heteroaryl); R2 = H, halo, NH2, etc.; R3 = (heterocycloalkyl)alkyl, heteroarylalkyl, arylalkyl, etc.], useful for treating or preventing diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl, were prepared E.g., a multi-step synthesis of II, starting from 4,6-dichloropyrimidine and p-trifluoromethoxyaniline, was given. The compds. I preferably show an IC50 in the range of 1x10⁻¹⁰ to 1x10⁻⁵M for Bcr-abl (specific data for one of the exemplified compds. I are given). The pharmaceutical composition comprising the compound I is claimed.


IT 778275-99-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)

RN 778275-99-3 CAPLUS

CN Benzamide, 3-[2-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI)
 (CA INDEX NAME)



L8 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:780678 CAPLUS

DN 141:277637

TI Preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives for inhibition of angiogenesis

IN Lee, Jinho; Kim, Hak Joong; Choi, Seihyun; Choi, Hwan Geun; Yoon, Seunghyun; Kim, Jong-Hyun; Jo, Kiwon; Kim, Semi; Koo, Sun-Young; Kim, Min-Hyeung; Kim, Jung In; Hong, Sang-Yong; Kim, Mi Sun; Ahn, Shinbyoung; Yoon, Hae-Seong; Cho, Heung-Soo

PA LG Life Sciences Ltd., S. Korea

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2004080979 | A1 | 20040923 | WO 2004-KR301 | 20040213 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI US 2003-454335P | P | 20030314 | | |

OS MARPAT 141:277637

AB Title compds. I [R1 = (hetero)aromatic ring; R2 = H, alkyl, aryl, etc.; R3 = H, alkyl, X1n1NX2X3, etc.; X1 = H, alkylene, etc.; X2 = H, alkoxy, pyrrolidine, etc.; n1 = 0-1; X3 = H, alkyl, (hetero)aryl, etc.] are prepared For instance, [3-(2-aminopyrimidin-4-yl)-4-hydroxyphenyl]phenylmethanone (II) is prepared from 3-(2-aminopyrimidin-4-yl)-4-benzyloxy-N-methoxy-N-methylbenzamide (preparation given) and bromobenzene (THF, n-BuLi, -78°) in 47.5% yield. II has IC50 > 0.1 µM for KDR kinase. I are angiogenesis receptor tyrosine kinases, in particular, VEGF receptor 2 kinase ('KDR'); they are useful for the treatment and prevention of angiogenesis-related diseases, particularly resulting from the unregulated or undesired KDR activity, such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy.


IT 761000-95-7P 761000-96-8P 761000-97-9P
 761001-02-9P 761001-03-0P 761001-04-1P
 761001-05-2P 761001-06-3P 761001-07-4P
 761001-08-5P 761001-09-6P 761001-10-9P
 761001-11-0P 761001-12-1P 761001-13-2P
 761001-14-3P 761001-15-4P 761001-16-5P
 761001-17-6P 761001-18-7P 761001-19-8P
 761001-37-0P 761001-38-1P 761001-39-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivs. for inhibition of angiogenesis)


RN 761000-95-7 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 761000-96-8 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl] (2-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 761000-97-9 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl] (2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 761001-02-9 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl] (2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 761001-03-0 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl] (2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 761001-04-1 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl] (2-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 761001-05-2 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl] [1,1'-biphenyl]-4-yl-
(9CI) (CA INDEX NAME)




RN 761001-06-3 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl] [1,1'-biphenyl]-3-yl-
(9CI) (CA INDEX NAME)




RN 761001-07-4 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl] (3-bromo-2,4-
difluoro-6-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 761001-08-5 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][4-(dimethylamino)-2-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 761001-09-6 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][4-chlorophenyl]- (9CI) (CA INDEX NAME)




RN 761001-10-9 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][2-chloro-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 761001-11-0 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][2-fluoro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-12-1 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][2-methyl-5-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-13-2 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][5-(diethylamino)-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 761001-14-3 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 761001-15-4 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 761001-16-5 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-17-6 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 761001-18-7 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-19-8 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl](4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 761001-37-0 CAPLUS

CN Methanone, (2-fluoro-4-methylphenyl)[4-hydroxy-3-{2-(methylamino)-4-pyrimidinyl}phenyl]- (9CI) (CA INDEX NAME)




RN 761001-38-1 CAPLUS

CN Methanone, (4-chloro-2-fluorophenyl)[4-hydroxy-3-{2-(methylamino)-4-pyrimidinyl}phenyl]- (9CI) (CA INDEX NAME)



RN 761001-39-2 CAPLUS

CN Glycine, N-[4-{5-(2-fluoro-4-methylbenzoyl)-2-hydroxyphenyl}-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 761001-56-3P 761001-57-4P 761001-67-6P


761001-68-7P 761001-78-9P 761001-79-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivs. for inhibition of angiogenesis)


RN 761001-56-3 CAPLUS

CN Benzoic acid, 3-(2-amino-4-pyrimidinyl)-4-(phenylmethoxy)-, methyl ester
(9CI) (CA INDEX NAME)




RN 761001-57-4 CAPLUS

CN Benzamide, 3-(2-amino-4-pyrimidinyl)-N-methoxy-N-methyl-4-(phenylmethoxy)-
(9CI) (CA INDEX NAME)




RN 761001-67-6 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-(phenylmethoxy)phenyl][3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 761001-68-7 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-(phenylmethoxy)phenyl][3-(chloromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-78-9 CAPLUS

CN Benzamide, N-methoxy-N-methyl-3-[2-(methyamino)-4-pyrimidinyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 761001-79-0 CAPLUS

CN Glycine, N-[4-[5-(2-fluoro-4-methylbenzoyl)-2-(phenylmethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:570980 CAPLUS
 DN 142:134488
 TI α -Enones in heterocyclic synthesis, Part I. Classical synthetic and environmentally friendly synthetic approaches to alkyl and acyl azoles and azines
 AU Al-Shiekh, Mariam A.; El-Din, Abdellatif M. Salah; Hafez, Ebtisam A.; Elnagdi, Mohamed H.
 CS Department of Chemistry, Girls College of Education, Jeddah, 21 341, Saudi Arabia
 SO Journal of Chemical Research (2004), (3), 174-179
 CODEN: JCROA4
 PB Science Reviews
 DT Journal
 LA English
 OS CASREACT 142:134488
 AB The utility of α -oxo enamines RCOCH:CHNMe_2 ($\text{R} = \text{Et}$, 4-MeCOC₆H₄) in the synthesis of several new azolotriazine, pyrazolo[3,4-d]pyridazine, isoxazolo[3,4-d]pyridazine, azolopyrimidine and pyridine derivs. on conventional heating or under microwave irradiation conditions, is reported.
 IT 825633-32-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of formazans, dioxo hydrazones, pyridines, pyrazolopyridazines, imidazopyrimidines and other mono- and bicyclic heterocycles from α -oxo enamines)
 RN 825633-32-7 CAPLUS
 CN Ethanone, 1-[4-(2-amino-4-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:451634 CAPLUS
 DN 141:23544
 TI Preparation of anilinopyrimidines as JNK pathway inhibitors for treating or preventing an inflammatory or metabolic condition
 IN Satoh, Yoshitaka; Bhagwat, Shripad S.
 PA USA
 SO U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 4,645.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | US 2004106634 | A1 | 20040603 | US 2003-395811 | 20030324 |
| | US 2003220330 | A1 | 20031127 | US 2001-4645 | 20011204 |
| | CA 2520440 | AA | 20041007 | CA 2004-2520440 | 20040324 |
| | WO 2004084901 | A1 | 20041007 | WO 2004-US9208 | 20040324 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | |
|------|-----------------|----|----------|
| PRAI | US 2000-251904P | P | 20001206 |
| | US 2001-4645 | A2 | 20011204 |
| | US 2003-395811 | A | 20030324 |
| | WO 2004-US9208 | W | 20040324 |

OS MARPAT 141:23544

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2, R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of $\leq 10 \mu\text{M}$ in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition (such as obesity).


IT 434945-24-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anilinopyrimidines as JNK pathway inhibitors for treating or preventing an inflammatory or metabolic condition)

RN 434945-24-1 CAPLUS

CN Benzoic acid, 4-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]- (9CI)
 (CA INDEX NAME)




IT 434950-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of anilinopyrimidines as JNK pathway inhibitors for treating or preventing an inflammatory or metabolic condition)

RN 434950-55-7 CAPLUS

CN Benzoic acid, 4-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:412938 CAPLUS
 DN 140:423692
 TI Pyridine and pyrimidine derivatives and their compositions, useful as inhibitors of JAK and other protein kinases
 IN Bethiel, Randy S.; Moon, Young Choon
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004041810 | A1 | 20040521 | WO 2003-US35188 | 20031105 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2507406 | AA | 20040521 | CA 2003-2507406 | 20031105 |
| | US 2004176271 | A1 | 20040909 | US 2003-702113 | 20031105 |
| | EP 1560824 | A1 | 20050810 | EP 2003-778111 | 20031105 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRAI | US 2002-424043P | P | 20021105 | | |
| | WO 2003-US35188 | W | 20031105 | | |

OS MARPAT 140:423692

AB The invention provides compds. of formula I or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compns. comprising I, and methods of utilizing I and their compns. in the treatment of various protein kinase-mediated disorders. In compds. I, R1 is Q-Ar1; Q is a bond or C1-2 alkylidene chain wherein one methylene unit is optionally replaced by O, NR, NRCO, NRCONR, NRCO2, CO, CO2, CONR, OC(O)NR, SO2, SO2NR, NRSO2, NRSO2NR, C(O)C(O), or C(O)CH2C(O); R is H or (un)substituted aliphatic; Ar1 is (un)substituted, (poly)(un)saturated, 5- to 7-membered monocyclic ring having 0-3 N/O/S heteroatoms, or 8- to 12-membered bicyclic ring system having 0-5 N/O/S heteroatoms; Z1 is N or CH; Z7 is N or CURy; T, U are bond or (un)saturated C1-6 alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO2, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO2, NRCONR, SO, SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR; Rx, Ry are independently halogen, CN, NO2, or R'; Z2, Z5, and Z6 are independently N or CH, provided that no more than 2 of them are N; Z3 is CR3; Z4 is CR4; wherein one of R3 and R4 is Ru and the other is OR'; Ru is (CH2)tCN, (CH2)tNO2, (CH2)tNR2, (CH2)tNRCOR, (CH2)tCONR2, (CH2)tCO2R, (CH2)tAr2, etc.; t is 0-2; Ar2 is an (un)substituted, (poly)(un)saturated 5- to 7-membered, monocyclic ring having 0-3 N/O/S heteroatoms; and R' is H, (un)substituted aliphatic or (bi)(hetero)cyclic. Approx. 190 compds. I are claimed individually. A general multi-step preparation is described in examples, including step combinations and final product mol. wts. for approx. 30 invention compds., including II. In a JAK3 inhibition assay, several invention compds. had Ki values less than 0.1 μ M. Similar

potencies were obtained for some compds. against CDK2, JNK3, SYK, and GSK-3.


IT 691895-11-1P 691895-12-2P 691895-13-3P
 691895-14-4P 691895-15-5P 691895-16-6P
 691895-17-7P 691895-18-8P 691895-19-9P
 691895-23-5P 691895-24-6P 691895-25-7P
 691895-26-8P 691895-27-9P 691895-28-0P
 691895-29-1P 691895-30-4P 691895-31-5P
 691895-32-6P 691895-33-7P 691895-34-8P
 691895-35-9P 691895-36-0P 691895-37-1P
 691895-38-2P 691895-39-3P 691895-40-6P
 691895-42-8P 691895-44-0P 691895-45-1P
 691895-46-2P 691895-47-3P 691895-48-4P
 691895-49-5P 691895-50-8P 691895-51-9P
 691895-52-0P 691895-53-1P 691895-54-2P
 691895-55-3P 691895-56-4P 691895-57-5P
 691895-58-6P 691895-59-7P 691895-60-0P
 691895-61-1P 691895-62-2P 691895-63-3P
 691895-64-4P 691895-65-5P 691895-66-6P
 691895-67-7P 691895-68-8P 691895-69-9P
 691895-70-2P 691895-71-3P 691895-72-4P
 691895-73-5P 691895-74-6P 691895-75-7P
 691895-76-8P 691895-77-9P 691895-78-0P
 691895-79-1P 691895-80-4P 691895-81-5P
 691895-82-6P 691895-83-7P 691895-84-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridine and pyrimidine derivs. as inhibitors of JAK and other protein kinases)


RN 691895-11-1 CAPLUS

CN Benzamide, 2-methoxy-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 691895-12-2 CAPLUS


CN Benzoic acid, 2-hydroxy-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-13-3 CAPLUS

CN Benzamide, 2-hydroxy-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

NAME)




RN 691895-14-4 CAPLUS

CN Benzoic acid, 2-hydroxy-N,N-dimethyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 691895-15-5 CAPLUS

CN Benzoic acid, 5-[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 691895-16-6 CAPLUS

CN Benzoic acid, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 691895-17-7 CAPLUS

CN Benzoic acid, 2-methoxy-5-[2-(phenylamino)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 691895-18-8 CAPLUS

CN Benzamide, 5-[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 691895-19-9 CAPLUS


CN Benzoic acid, 2-methoxy-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-23-5 CAPLUS

CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-hydroxy-
(9CI) (CA INDEX NAME)

RN 691895-24-6 CAPLUS


CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)
(CA INDEX NAME)

RN 691895-25-7 CAPLUS

CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)
(CA INDEX NAME)


RN 691895-26-8 CAPLUS

CN Benzamide, 5-[2-[(3,4-dimethylphenyl)amino]-4-pyrimidinyl]-2-hydroxy-
(9CI) (CA INDEX NAME)




RN 691895-27-9 CAPLUS

CN Benzamide, 2-hydroxy-5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 691895-28-0 CAPLUS

CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)
(CA INDEX NAME)




RN 691895-29-1 CAPLUS

CN Benzamide, 5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-30-4 CAPLUS

CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-31-5 CAPLUS

CN Benzamide, 2-methoxy-5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 691895-32-6 CAPLUS

CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-33-7 CAPLUS

CN Benzamide, 2-methoxy-5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 691895-34-8 CAPLUS

CN Benzamide, 5-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-35-9 CAPLUS

CN Benzamide, 5-[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 691895-36-0 CAPLUS

CN Benzamide, 5-[2-[(3,4-difluorophenyl)amino]-4-pyrimidinyl]-2-methoxy-
(9CI) (CA INDEX NAME)




RN 691895-37-1 CAPLUS

CN Benzamide, 5-[2-[(3,4-dimethylphenyl)amino]-4-pyrimidinyl]-2-methoxy-
(9CI) (CA INDEX NAME)




RN 691895-38-2 CAPLUS

CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-39-3 CAPLUS

CN Benzoic acid, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 691895-40-6 CAPLUS

CN Benzoic acid, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-ethoxy-, (9CI) (CA INDEX NAME)




RN 691895-42-8 CAPLUS

CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-ethoxy-, (9CI) (CA INDEX NAME)




RN 691895-44-0 CAPLUS

CN Benzamide, 5-[2-(phenylamino)-4-pyrimidinyl]-2-propoxy- (9CI) (CA INDEX NAME)




RN 691895-45-1 CAPLUS

CN Benzamide, 2-(1-methylethoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-46-2 CAPLUS

CN Benzamide, 2-(cyclohexylmethoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-47-3 CAPLUS

CN Benzamide, 2-(cyclopropylmethoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-48-4 CAPLUS

CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 691895-49-5 CAPLUS

CN Benzamide, 2-methoxy-5-[2-[(3-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-50-8 CAPLUS

CN Benzamide, 2-[(3-methoxyphenyl)methoxy]-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-51-9 CAPLUS

CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-
(9CI) (CA INDEX NAME)




RN 691895-52-0 CAPLUS

CN Benzamide, 2-(2-methylpropoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 691895-53-1 CAPLUS

CN Benzamide, 2-(2-ethylbutoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)




RN 691895-54-2 CAPLUS

CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-
(9CI) (CA INDEX NAME)




RN 691895-55-3 CAPLUS

CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-
(9CI) (CA INDEX NAME)




RN 691895-56-4 CAPLUS

CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-57-5 CAPLUS

CN Benzamide, 5-[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-58-6 CAPLUS

CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-59-7 CAPLUS

CN Benzamide, 5-[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-60-0 CAPLUS

CN Benzamide, 5-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-61-1 CAPLUS

CN Benzoic acid, 3-[[4-(3-(aminocarbonyl)-4-(1-methylethoxy)phenyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 691895-62-2 CAPLUS

CN Benzoamide, 2-(1-methylethoxy)-5-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-63-3 CAPLUS

CN Benzoamide, 2-(1-methylethoxy)-5-[2-[(3-phenoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-64-4 CAPLUS

CN Benzamide, 5-[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-65-5 CAPLUS

CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-66-6 CAPLUS

CN Benzamide, 5-[2-[(3,4-difluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-67-7 CAPLUS

CN Benzamide, 5-[2-[(4-chloro-3-cyanophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 691895-68-8 CAPLUS


CN Benzamide, 5-[2-[(3,5-dichlorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 691895-69-9 CAPLUS

CN Benzoic acid, 5-[2-(phenylamino)-4-pyrimidinyl]-2-[[(3R)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-70-2 CAPLUS

CN Benzoic acid, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-[(3R)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-71-3 CAPLUS

CN Benzoic acid, 5-[2-(phenylamino)-4-pyrimidinyl]-2-[(3S)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-72-4 CAPLUS

CN Benzoic acid, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-[(3S)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-73-5 CAPLUS

CN Benzoic acid, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-[(3R)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-74-6 CAPLUS

CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-N,N-dimethyl-2-[[[(3R)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-75-7 CAPLUS

CN Benzamide, 5-[2-(phenylamino)-4-pyrimidinyl]-2-[[[(3R)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-76-8 CAPLUS

CN Benzamide, N,N-dimethyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-[[(3R)-tetrahydro-3-furanyloxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-77-9 CAPLUS

CN Benzamide, 5-[2-(phenylamino)-4-pyrimidinyl]-2-[[(3S)-tetrahydro-3-furanyloxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-78-0 CAPLUS

CN Benzamide, N,N-dimethyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-[[(3S)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-79-1 CAPLUS

CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-[[(3S)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-80-4 CAPLUS


CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-N,N-dimethyl-2-[[(3S)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 691895-81-5 CAPLUS

CN Benzamide, 2-methoxy-N-methyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 691895-82-6 CAPLUS

CN Benzamide, 2-methoxy-N,N-dimethyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 691895-83-7 CAPLUS

CN Benzamide, 2-methoxy-5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 691895-84-8 CAPLUS

CN Benzamide, 2-methoxy-5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L8 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:412924 CAPLUS
 DN 140:423690
 TI Pyridine and pyrimidine derivatives and their compositions, useful as
 inhibitors of JAK and other protein kinases
 IN Ledebor, Mark; Ledford, Brian
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 122 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2004041789 | A1 | 20040521 | WO 2003-US34991 | 20031103 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2506772 | AA | 20040521 | CA 2003-2506772 | 20031103 |
| | US 2004147507 | A1 | 20040729 | US 2003-700333 | 20031103 |
| | EP 1562911 | A1 | 20050817 | EP 2003-778092 | 20031103 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| PRAI | US 2002-422973P | P | 20021101 | | |
| | WO 2003-US34991 | W | 20031103 | | |

OS MARPAT 140:423690

AB The invention provides a compound of formula I or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compns. comprising I, and methods of utilizing I and their compns. in the treatment of various protein kinase-mediated disorders. In compds. I, R1 is Q-Ar1; Q is a C1-2 alkylidene chain wherein one methylene unit is optionally replaced by O, NR, NRCO, NRCONR, NRCO2, CO, CO2, CONR, OC(O)NR, SO2, SO2NR, NRSO2, NRSO2NR, C(O)C(O), or C(O)CH2C(O); R is H or (un)substituted aliphatic; Ar1 is (un)substituted, (poly)(un)saturated, 5- to 7-membered monocyclic ring having 0-3 N/O/S heteroatoms, or 8- to 12-membered bicyclic ring system having 0-5 N/O/S heteroatoms; Z1 is N or CH; Z7 is N or C(U)nRy; T, U are bond or (un)saturated C1-6 alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO2, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO2, NRCONR, SO, SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR; m, n are independently 0 or 1; Rx, Ry are independently R or Ar1; Z2 is N or CR2; Z3 is N or CR3; Z4 is N or CR4; Z5 is N or CR5; and Z6 is N or CR6; wherein each occurrence of R2, R3, R4, R5, or R6 is independently Ru or (V)pRv, provided that (a) no more than 3 of Z2, Z3, Z4, Z5 or Z6 are N, and (b) at least one of Z3, Z4 or Z5 is CR3, CR4, or CR5, resp., and at least one of R3, R4, or R5 is Ru, each occurrence of Ru is NRCOR7, CONR(R7), SO2NR(R7), NRSO2R7, NRCONR(R7), NRSO2NR(R7), or CONRNR(R7), wherein R7 is (CH2)t-Y-R8; and t is 0-2. Furthermore, Y is bond, O, S, NR9, OCH2, SCH2, NR9CH2, O(CH2)2, S(CH2)2, or NR9(CH2)2; R5 is Ar2, or NR8R9 is (un)substituted 5- to 8-membered heterocyclyl or heteroaryl having 1-3 N/O/S heteroatoms; each occurrence of V is bond or (un)saturated

C1-6 alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO₂, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO₂, NRCONR, SO, SO₂, NRSO₂, SO₂NR, NRSO₂NR, O, S, or NR; each occurrence of p is 0 or 1; each occurrence of R_v is R or Ar₂; and Ar₂ is an (un)substituted, (poly)(un)saturated 5- to 7-membered, monocyclic ring having 0-3 N/O/S heteroatoms, or an 8- to 12-membered, bicyclic ring system having 0-5 N/O/S heteroatoms. It is further provided that: (a) when Z₁ is N, and Z₇ is CH, and ring B is Ph, and at least one of R₃ or R₄ is NHCOR₇, then R₁ is not Ph which is only substituted with two or three occurrences of OR'; and also that (b) when Z₁ is N, and Z₇ is CH, and ring B is Ph, and at least one of R₃ or R₄ is NHCOR₇, SO₂R₇, or CONRR₇, then R₁ is not Ph which is only substituted with one occurrence of -CON(R')₂ in the para-position, where R' is H, (un)substituted aliphatic or (bi)(hetero)cyclic. Approx. 100 compds. I are claimed individually, and several compds. were prepared in examples. For instance, 3-aminoacetophenone was amidated with 2-furoyl chloride, and the resultant N-(3-acetylphenyl)amide underwent condensation with DMF di-Me acetal at the acetyl Me group, with partial N-methylation at the amide. Cyclocondensation of the resultant mixture of β-(dimethylamino)-α,β-unsatd. ketones with (3-methoxyphenyl)guanidine gave a mixture of invention compds. II [R = H, Me]. In a JAK3 inhibition assay, several invention compds. including II [R = Me] had K_i values of 1.0 μM or less. Similar potencies were obtained for some compds. against CDK2, JNK3, and (no data) ZAP-70.


IT 692733-87-2P 692733-88-3P 692733-89-4P
 692733-90-7P 692733-91-8P 692733-92-9P
 692733-93-0P 692733-94-1P 692733-95-2P
 692733-96-3P 692733-97-4P 692733-98-5P
 692733-99-6P 692734-00-2P 692734-01-3P
 692734-02-4P 692734-03-5P 692734-04-6P
 692734-05-7P 692734-06-8P 692734-07-9P
 692734-08-0P 692734-09-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridine and pyrimidine derivs. as inhibitors of JAK and other protein kinases)


RN 692733-87-2 CAPLUS

CN Piperidine, 1-[2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]benzoyl]- (9CI)
 (CA INDEX NAME)




RN 692733-88-3 CAPLUS

CN Benzamide, 2-methyl-N-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692733-89-4 CAPLUS

CN Benzamide, N-cyclohexyl-2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 692733-90-7 CAPLUS

CN Benzamide, 2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)-
(9CI) (CA INDEX NAME)




RN 692733-91-8 CAPLUS

CN Benzamide, 2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 692733-92-9 CAPLUS

CN Benzamide, 2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 692733-93-0 CAPLUS

CN Benzamide, N-(cyclohexylmethyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 692733-94-1 CAPLUS

CN Benzamide, N-(2-furanylmethyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 692733-95-2 CAPLUS

CN Benzamide, N-(1-naphthalenylmethyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 692733-96-3 CAPLUS

CN Benzamide, 3-[2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)- (9CI)
(CA INDEX NAME)




RN 692733-97-4 CAPLUS

CN Benzamide, N-[(2,3-dichlorophenyl)methyl]-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692733-98-5 CAPLUS

CN Benzamide, 3-[2-(phenylamino)-4-pyrimidinyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 692733-99-6 CAPLUS

CN Benzamide, N-[2-(1H-imidazol-4-yl)ethyl]-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692734-00-2 CAPLUS

CN Benzamide, N-[(2,5-difluorophenyl)methyl]-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692734-01-3 CAPLUS

CN Benzamide, 3-[2-(phenylamino)-4-pyrimidinyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 692734-02-4 CAPLUS

CN Piperidine, 1-[4-[2-(phenylamino)-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 692734-03-5 CAPLUS

CN Benzamide, 4-[2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 692734-04-6 CAPLUS

CN Benzamide, N-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692734-05-7 CAPLUS

CN Benzamide, N-cyclohexyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692734-06-8 CAPLUS

CN Benzamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 692734-07-9 CAPLUS

CN Piperidine, 1-[4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 692734-08-0 CAPLUS

CN Benzamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 692734-09-1 CAPLUS

CN Benzamide, N-cyclohexyl-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



L8 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:162676 CAPLUS

DN 140:199343

TI Preparation of aminopyrimidine derivatives as protein kinase inhibitors

IN Cochran, John; Green, Jeremy; Hale, Michael R.; Ledford, Brian; Maltais, Francois; Nanthakumar, Suganthini

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN, CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004016597 | A2 | 20040226 | WO 2003-US25333 | 20030812 |
| | WO 2004016597 | A3 | 20040422 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2495386 | AA | 20040226 | CA 2003-2495386 | 20030812 |
| | US 2004106615 | A1 | 20040603 | US 2003-639784 | 20030812 |
| | BR 2003013397 | A | 20050628 | BR 2003-13397 | 20030812 |
| | EP 1546117 | A2 | 20050629 | EP 2003-788433 | 20030812 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | NO 2005001207 | A | 20050518 | NO 2005-1207 | 20050308 |
| PRAI | US 2002-403256P | P | 20020814 | | |
| | US 2002-416802P | P | 20021008 | | |
| | WO 2003-US25333 | W | 20030812 | | |

OS MARPAT 140:199343


AB Title compds. I [wherein B = 6-membered aryl ring with 0-3 N atoms, Z1, Z2 = independently N, CH; T, Q = independently saturated or unsatd. alkylidene; U = NH and derivs., NHCO2 and derivs., o, CONH and derivs., CO, CO2, OCO, NHSO2 and derivs., SO2NH and derivs., SO2, etc.; m, n = independently 0 or 1; p = 0-4; R1 = R or Ar; R = H, (un)substituted aliphatic group; Ar = (un)substituted 6-10 membered aryl ring, 5-10 membered heteroaryl ring having 1-4 heteroatoms, or a 3-10 heterocyclyl membered ring having 1-4 heteroatoms; R3 = R, Ar, (CH2)yCH(R5)2 or CN; y = 0-6; R2 = (CH2)yCH(R5)2, (CH2)yCH(R4)CH(R5)2; R4 = R, (CH2)wOR, (CH2)wN(R)2 or (CH2)wSR; w = 0-4; R5 = independently Ar, OR, CO2R, SR, SO2R, CN, N(Ar)(R), (un)substituted aliphatic, etc.; R6 = independently R, F, Cl, NH2 and derivs., OR, SR, SO2R, NRSO2R, CN, SO2N(R)2, etc.; and their pharmaceutically acceptable salts] were prepared as protein kinase inhibitors (no data). For example, II was prepared in 3 steps by Pd-cross coupling of 2,4-dichloro-5-fluoropyrimidine with 4-methoxycarbonylphenyl boronic acid (III); acylation of (S)-3-chlorophenyl glycinol with III, and alkylation of isopropylamine with 2-chloropyrimidine intermediate. I and their formulations are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation (no data).

IT 663611-45-8P, 3-[2-(Phenylamino)pyrimidin-4-yl]benzoic acid
 663611-50-5P 663611-51-6P 663611-63-0P
 663611-64-1P 663611-66-3P, 4-[5-Chloro-2-(cyclopropylamino)pyrimidin-4-yl]benzoic acid methyl ester
 663611-67-4P, 4-[5-Chloro-2-(cyclopropylamino)pyrimidin-4-yl]benzoic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)
 RN 663611-45-8 CAPLUS
 CN Benzoic acid, 3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 663611-50-5 CAPLUS
 CN Benzoic acid, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663611-51-6 CAPLUS
 CN Benzoic acid, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-63-0 CAPLUS

CN Benzoic acid, 4-[5-chloro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-64-1 CAPLUS


CN Benzoic acid, 4-[5-chloro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663611-66-3 CAPLUS

CN Benzoic acid, 4-[5-chloro-2-(cyclopropylamino)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 663611-67-4 CAPLUS

CN Benzoic acid, 4-[5-chloro-2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 216959-98-7, 4-(2-Aminopyrimidin-4-yl)benzoic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)

RN 216959-98-7 CAPLUS

CN Benzoic acid, 4-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




IT 663611-53-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)

RN 663611-53-8 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 663611-48-1P 663611-52-7P 663611-57-2P
 663611-59-4P 663611-62-9P 663611-65-2P
 663611-71-0P 663611-74-3P 663611-75-4P
 663611-77-6P 663611-82-3P 663611-84-5P
 663612-19-9P 663612-20-2P 663612-21-3P
 663612-22-4P 663612-23-5P 663612-24-6P
 663612-25-7P 663612-27-9P 663612-28-0P
 663612-29-1P 663612-30-4P 663612-31-5P
 663612-32-6P 663612-33-7P 663612-34-8P
 663612-35-9P 663612-42-8P 663612-81-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)

RN 663611-48-1 CAPLUS

CN Benzamide, 4-[5-chloro-2-[[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Electro Species.

RN 663611-52-7 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-57-2 CAPLUS

CN Benzamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-59-4 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-62-9 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-65-2 CAPLUS

CN Benzamide, 4-[5-chloro-2-(cyclopropylamino)-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-71-0 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-74-3 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-(cyclopropylamino)-5-fluoro-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-75-4 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-77-6 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3-methyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 663611-82-3 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-84-5 CAPLUS

CN Benzamide, 4-[5-chloro-2-(ethoxyamino)-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-19-9 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-20-2 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-21-3 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-22-4 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1-methylethyl)amino]-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-23-5 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-24-6 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663612-25-7 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[[1S]-2-

hydroxy-1-methylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-27-9 CAPLUS

CN Benzamide, 4-[5-chloro-2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-28-0 CAPLUS

CN Benzamide, 4-[5-fluoro-2-[(1-methylethyl)amino]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-29-1 CAPLUS

CN Benzamide, 4-[5-fluoro-2-[[[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-30-4 CAPLUS

CN Benzamide, 4-[2-(cyclopropylamino)-5-fluoro-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663612-31-5 CAPLUS

CN Benzamide, 4-[2-[[[(1S)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-32-6 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[(1S)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-33-7 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-34-8 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[(1S)-2-hydroxy-1-methylethylamino]-4-pyrimidinyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-35-9 CAPLUS

CN Benzamide, 4-[2-[(1S)-2-hydroxy-1-methylethylamino]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-42-8 CAPLUS

CN Benzamide, 4-[5-chloro-2-[[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-81-5 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:837045 CAPLUS
 DN 139:337995
 TI Preparation of benzamides as histone deacetylase inhibitors
 IN Stokes, Elaine Sophie Elizabeth; Roberts, Craig Anthony; Waring, Michael James
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2003087057 | A1 | 20031023 | WO 2003-GB1442 | 20030402 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2480356 | AA | 20031023 | CA 2003-2480356 | 20030402 |
| | BR 2003008875 | A | 20050104 | BR 2003-8875 | 20030402 |
| | EP 1495002 | A1 | 20050112 | EP 2003-712442 | 20030402 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | US 2005171103 | A1 | 20050804 | US 2003-509941 | 20030402 |
| | JP 2005533011 | T2 | 20051104 | JP 2003-584013 | 20030402 |
| | NO 2004004444 | A | 20041228 | NO 2004-4444 | 20041019 |
| PRAI | GB 2002-7863 | A | 20020405 | | |
| | GB 2002-29930 | A | 20021221 | | |
| | WO 2003-GB1442 | W | 20030402 | | |

OS MARPAT 139:337995

AB The title compds. [I; ring A = heterocyclyl; m = 0-4; R1 = OH, halo, CF3, CN, etc.; R2 = halo; n = 0-2; R3 = NH2, OH; R4 = OH, halo, CF3, CN, etc.; p = 0-4; or pharmaceutically-acceptable salts or in-vivo-hydrolysable esters or amides thereof], useful in the treatment of diseases or medical conditions mediated by histone deacetylase such as cancer, were prepared Thus, deprotection of N-(2-tert-butoxycarbonylaminophenyl)-4-(pyridin-4-yl)benzamide (preparation given) with 4M HCl solution in dioxane afforded 46% I.HCl [A = pyridin-4-yl; R2 = H; R3 = NH2; R4 = H]. The compds. I showed IC50 of < 50.0 µM in in vitro enzyme assay of pooled histone deacetylases. Pharmaceutical composition comprising the compound I is claimed.

IT 617702-02-0P 617702-08-6P 617702-09-7P
 617702-10-0P 617702-11-1P 617702-12-2P
 617702-13-3P 617702-14-4P 617702-15-5P
 617702-16-6P 617702-17-7P 617702-39-3P
 617702-40-6P 617702-41-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamides as histone deacetylase inhibitors)

RN 617702-02-0 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-(2-amino-4-pyrimidinyl)-, hydrochloride


(9CI) (CA INDEX NAME)



●x HCl


RN 617702-08-6 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 617702-09-7 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 617702-10-0 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[[3-(1-piperidinyl)propyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 617702-11-1 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 617702-12-2 CAPLUS
 CN Benzamide, N-(2-aminophenyl)-4-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 617702-13-3 CAPLUS
 CN Benzamide, N-(2-aminophenyl)-4-[2-[[4-(diethylamino)butyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 617702-14-4 CAPLUS
 CN Benzamide, N-(2-aminophenyl)-4-[2-[[2-(diethylamino)ethyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 617702-15-5 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-pyridinylmethyl)amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 617702-16-6 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[[2-(1-piperidinyl)ethyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 617702-17-7 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 617702-39-3 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[[3-[2-(dimethylamino)ethoxy]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 617702-40-6 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[[3-(methylphenylamino)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 617702-41-7 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[[2-(dibutylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 617702-97-3P 617703-05-6P 617703-06-7P

617703-09-0P 617703-10-3P 617703-11-4P

617703-12-5P 617703-13-6P 617703-14-7P

617703-15-8P 617703-16-9P 617703-17-0P

617703-18-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of benzamides as histone deacetylase inhibitors)


RN 617702-97-3 CAPLUS

CN Carbamic acid, [2-[[4-(2-amino-4-pyrimidinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 617703-05-6 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 617703-06-7 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 617703-09-0 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 617703-10-3 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-11-4 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[3-(1-piperidinyl)propyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-12-5 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-13-6 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-14-7 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[4-(diethylamino)butyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-15-8 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[2-(diethylamino)ethyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-16-9 CAPLUS

CN Carbamic acid, [2-[[4-[2-[(3-pyridinylmethyl)amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-17-0 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[2-(1-piperidiny)ethyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 617703-18-1 CAPLUS

CN Carbamic acid, [2-[[4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:633697 CAPLUS
 DN 139:180090
 TI Preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate
 receptor antagonists for the treatment of neurological disorders
 IN Adam, Geo; Goetschi, Erwin; Wichmann, Juergen; Woltering, Thomas Johannes
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 323 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2003066623 | A1 | 20030814 | WO 2003-EP859 | 20030128 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2003166639 | A1 | 20030904 | US 2003-350713 | 20030124 |
| | US 6949542 | B2 | 20050927 | | |
| | CA 2474219 | AA | 20030814 | CA 2003-2474219 | 20030128 |
| | BR 2003007474 | A | 20041109 | BR 2003-7474 | 20030128 |
| | EP 1474416 | A1 | 20041110 | EP 2003-702549 | 20030128 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005522440 | T2 | 20050728 | JP 2003-565996 | 20030128 |
| | NO 2004003237 | A | 20040802 | NO 2004-3237 | 20040802 |
| PRAI | EP 2002-2012 | A | 20020206 | | |
| | WO 2003-EP859 | W | 20030128 | | |

OS MARPAT 139:180090

AB This invention relates to dihydrobenzo[b][1,4]diazepin-2-ones (shown as I;
 variables defined below; e.g. 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-
 dihydrobenzo[b][1,4]diazepin-2-one). The invention further relates to
 medicaments containing these compds., a process for their preparation as well
 as


their use for preparation of medicaments for the treatment or prevention of
 acute and/or chronic neurol. disorders, e.g. Alzheimer's disease. Three
 examples of pharmaceutical compns. containing I are included. Ki values for
 50 examples of I as metabotropic glutamate receptor antagonists are
 tabulated, e.g. 0.00135 μ M for 7,8-dichloro-4-(3-pyridin-3-ylphenyl)-
 1,3-dihydrobenzo[b][1,4]diazepin-2-one. More than 400 example preps. of
 I and many example preps. of intermediates are included. For example,
 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-
 one (310 mg) was prepared from 4,5-dichlorophenylenediamine (0.97 mmol) and
 3-oxo-3-[3-(pyridin-3-yl)phenyl]propionic acid tert-Bu ester (0.97 mmol)
 by refluxing in xylene. For I: X is a single bond or an ethynediyl group;
 and wherein in case X is a single bond, R1 is H, cyano, halogen, lower
 alkyl, lower alkoxy, fluoro-lower alkyl, fluoro-lower alkoxy, pyrrol-1-yl,
 or Ph, which is (un)substituted by one or two substituents halogen, lower
 alkyl or fluoro-lower alkyl; or in case X is an ethynediyl group, R1 is
 Ph, which is (un)substituted by one or two substituents halogen, lower

alkyl or fluoro-lower alkyl. R2 is H, lower alkyl, lower alkenyl lower alkoxy, halogen, -NR'R'', pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, fluoro-lower alkyl, fluoro-lower alkoxy, or lower alkoxy(ethoxy)m; m = 1-4; R' is H, lower alkyl or C3-C6-cycloalkyl; R'' is H, lower alkyl or C3-C6-cycloalkyl; Y is -CH= or =N-; R3 is a six-membered aromatic heterocycle containing 1 to 3-N atoms or a pyridine N-oxide, which rings are (un)substituted by one or two substituents halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, amino, lower alkylamino, lower alkoxy-lower alkylamino, lower hydroxy-lower alkylamino, -(CH2)n-C(O)-OR'', -(CH2)n-C(O)-NR'R'', -(CH2)n-SO2-NR'R'', -(CH2)n-C(NH2):NR'', hydroxy, lower alkoxy, lower alkylthio, C3-C6-cycloalkyl and lower alkyl, which is (un)substituted by fluoro, -NR'R'', hydroxy, lower alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano or carbamoyloxy; n = 0-4.

IT 579476-49-6P, 3-(2-Aminopyrimidin-4-yl)benzoic acid methyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for treatment of neurol. disorders)

RN 579476-49-6 CAPLUS

CN Benzoic acid, 3-(2-amino-4-pyrimidinyl)-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:300895 CAPLUS

DN 138:321288

TI Preparation of 2- and 4-aminopyrimidines N-substituted by a bicyclic ring for use as kinase inhibitors in the treatment of cancer

IN Nagarathnam, Dhanapalan; Wang, Chunguang; Chen, Yuanwei; Yi, Lin; Chen, Jianqing; Weber, Olaf; Boyer, Stephen; Clark, Roger B.; Phillips, Barton; Meahl, Jennifer; Ladouceur, Gaetan; Bi, Cheng; Burke, Michael J.; Cook, James; Verma, Sharad K.; Fan, Jianmei

PA Bayer Corporation, USA

SO PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2003030909 | A1 | 20030417 | WO 2002-US30616 | 20020925 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI US 2001-324276P P 20010925

US 2002-352509P P 20020131

OS MARPAT 138:321288

AB The title compds. [I; X = NR1R6, NR4R5, R4, with the proviso that at least one X must be NR1R6; R1 = (un)substituted fused bicyclic unsatd. ring containing 9 or 10 atoms optionally containing 1-4 heteroatoms selected from the

group consisting of N, S and O; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, thio; R4 = (un)substituted -Yn-mono-ring group or -Yn-multi-ring group (each ring containing 4-18 atoms in the ring and optionally containing 1-4 heteroatoms selected from N, S, and O; n = 0-1; Y = alkylene, C(CN); R4 can also be hydrogen or alkyl when R5 is present); R5 = (un)substituted -Yn-mono-ring group or -Yn-multi-ring group (each ring containing 4-18 atoms in the ring and optionally containing 1-4 heteroatoms selected from N, S, and O; n = 0-1; Y = alkylene, N:CH, N:CHMe; with the proviso that the multi-ring group cannot be benzimidazolyl); R6 = H, alkyl] which are kinase inhibitors useful in the treatment of cancer and viral infections, were prepared and formulated. Thus, heating 6-aminoquinoline with 2,4-dichloro-5-trifluoromethylpyrimidine (preparation given) in the presence of Na2CO3 in BuOH to 120°C for 3 days afforded I [X = 6-quinolinylamino; R2 = CF3; R3 = H] which showed IC50 of 0.48 µM in in vitro proliferation inhibition assay (HCT 116 human colorectal carcinoma cells).


IT 511248-67-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 2- and 4-aminopyrimidines as kinase inhibitors in the treatment of cancer)

RN 511248-67-2 CAPLUS

CN Benzoic acid, 4-[5-fluoro-2-(6-quinolinylamino)-4-pyrimidinyl]-, butyl ester (9CI) (CA INDEX NAME)




IT 511244-94-3P 511245-08-2P 511248-71-8P
511248-82-1P 511248-83-2P 511248-87-6P
511248-99-0P 511249-07-3P 511249-08-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2- and 4-aminopyrimidines as kinase inhibitors in the treatment of cancer)


RN 511244-94-3 CAPLUS

CN Benzoic acid, 4-[5-fluoro-2-(6-quinolinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 511245-08-2 CAPLUS

CN Ethanone, 1-[4-[5-fluoro-2-(6-quinolinylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 511248-71-8 CAPLUS


CN Ethanone, 1-[3-[5-fluoro-2-(6-quinolinylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 511248-82-1 CAPLUS


CN Ethanone, 1-[4-[2-(6-quinolinylamino)-5-(trifluoromethyl)-4-

pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 511248-83-2 CAPLUS

CN Ethanone, 1-[4-[5-chloro-2-(6-quinolinylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 511248-87-6 CAPLUS

CN Ethanone, 1-[4-[5-fluoro-2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 511248-99-0 CAPLUS

CN Ethanone, 1-[4-[5-fluoro-2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 511249-07-3 CAPLUS

CN Benzoic acid, 4-[5-fluoro-2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]-, butyl ester (9CI) (CA INDEX NAME)



RN 511249-08-4 CAPLUS

CN Benzoic acid, 4-[5-fluoro-2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:814853 CAPLUS
 DN 137:325431
 TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
 IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manjo; Levine, Barry H.
 PA USA
 SO U.S. Pat. Appl. Publ., 134 pp., Cont.-in-part of U.S. 6,417,185.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2002156087 | A1 | 20021024 | US 2001-949035 | 20010906 |
| | US 6417185 | B1 | 20020709 | US 1999-336038 | 19990618 |
| PRAI | US 1999-336038 | A2 | 19990618 | | |
| | US 2000-230480P | P | 20000906 | | |
| | US 1998-89978P | P | 19980619 | | |

OS MARPAT 137:325431

AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidiny, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidiny, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3 β in a cell free assay with IC50 values of < 1 μ M. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).

IT 252904-09-9P, Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-[(5-nitro-2-pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- 252904-11-3P, Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-13-5P, Benzamide, N-[(3-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-31-7P, Benzamide, 4-[2-[[2-(2-pyridinylamino)ethyl]amino]-4-pyrimidinyl]- 252904-32-8P, Benzamide, 4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- 252904-33-9P, Benzamide, 4-[2-[[2-[(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-34-0P, Benzamide, 4-[2-[[3-(1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- 252904-35-1P, Benzamide, 4-[2-[[3-(2-naphthalenyloxy)propyl]amino]-

Same
 as
 # 17


4-pyrimidinyl]- 252904-36-2P, Benzenepropanamide,
 α -[[4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]benzoyl]amino]-
 , (α S)-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase
 3 inhibitors)


RN 252904-09-9 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-[(5-nitro-2-
 pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 252904-11-3 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-cyano-2-
 pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-13-5 CAPLUS

CN Benzamide, N-[(3-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-
 pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




PAGE 1-B

— OMe


RN 252904-31-7 CAPLUS

CN Benzamide, 4-[2-[[2-(2-pyridinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI)
 (CA INDEX NAME)




RN 252904-32-8 CAPLUS

CN Benzamide, 4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 252904-33-9 CAPLUS

CN Benzamide, 4-[2-[[2-[(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 252904-34-0 CAPLUS

CN Benzamide, 4-[2-[[3-(1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-35-1 CAPLUS


CN Benzamide, 4-[2-[[3-(2-naphthalenyloxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RN 252904-36-2 CAPLUS

CN Benzenepropanamide, α-[[4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 403806-71-3, 4-[2-[(4-Pyridylmethyl)amino]pyrimidin-4-yl]benzamide
403806-72-4 403806-74-6, 4-[2-[[3-Methylphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-75-7,
4-[2-[[4-Aminophenyl)methyl]amino]pyrimidin-4-yl]benzamide
403806-76-8, 4-[2-[[5-Methylpyrazin-2-yl)methyl]amino]pyrimidin-4-yl]benzamide 403806-78-0, 4-[2-[(3-Imidazolylpropyl)amino]pyrimidin-4-yl]benzamide 403806-80-4, 4-[2-[[4-

Cyanophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-81-5,
 4-[2-[[[3-Methoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403806-82-6, 4-[2-[[[4-Methoxyphenyl)methyl]amino]pyrimidin-4-
 yl]benzamide 403806-83-7, 4-[2-[[2-(4-
 Fluorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide 403806-87-1,
 4-[2-[[[3-Chlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403806-92-8, 4-[2-[[[4-Phenylbutyl]amino]pyrimidin-4-yl]benzamide
 403806-94-0, 4-[2-[[2-(3-Methoxyphenyl)ethyl]amino]pyrimidin-4-
 yl]benzamide 403806-96-2, 4-[2-[[3-Phenoxypropyl]amino]pyrimidin-
 4-yl]benzamide 403806-98-4, 4-[2-[[[3-
 Nitrophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-02-3,
 4-[2-[[2-(3-Chlorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide
 403807-03-4, 4-[2-[[Naphthylmethyl]amino]pyrimidin-4-yl]benzamide
 403807-10-3, 4-[2-[[3-(3-Methylphenoxy)propyl]amino]pyrimidin-4-
 yl]benzamide 403807-11-4, 4-[2-[[2-(2H-Benzo[3,4-d]-1,3-dioxolan-
 5-yl)ethyl]amino]pyrimidin-4-yl]benzamide 403807-12-5,
 4-[2-[[2-(4-Nitrophenyl)ethyl]amino]pyrimidin-4-yl]benzamide
 403807-13-6, 4-[2-[[[2,6-Dimethoxyphenyl)methyl]amino]pyrimidin-4-
 yl]benzamide 403807-14-7, 4-[2-[[[3,4-
 Dimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-19-2
 , 4-[2-[[[3-(Trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-20-5, 4-[2-[[[4-(Trifluoromethyl)phenyl)methyl]amino]pyrimi-
 din-4-yl]benzamide 403807-21-6, 4-[2-[[[3,5-
 Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-23-8
 , 4-[2-[[[2,4-Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-27-2, 4-[2-[[3-(3-Methoxyphenoxy)propyl]amino]pyrimidin-4-
 yl]benzamide 403807-32-9, 4-[2-[[3-[4-(2,4-
 Dichlorophenyl)imidazolyl]propyl]amino]pyrimidin-4-yl]benzamide
 403807-33-0, 4-[2-[[3-[4-(3-Methoxyphenyl)imidazolyl]propyl]amino]
 pyrimidin-4-yl]benzamide 403807-36-3, 4-[2-[[3-(4-
 Chlorophenoxy)propyl]amino]pyrimidin-4-yl]benzamide 403807-37-4,
 4-[2-[[[4-Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-38-5, 4-[2-[[[4-(4-Fluorophenyl)phenyl)methyl]amino]pyrimid-
 in-4-yl]benzamide 403807-39-6, 4-[2-[[[3-
 Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-43-2,
 4-[2-[[2-(Benzothiazol-2-ylamino)ethyl]amino]pyrimidin-4-yl]benzamide
 403807-46-5, 4-[2-[[2,2-Diphenylethyl]amino]pyrimidin-4-
 yl]benzamide 403807-47-6, 4-[2-[[[3,4,5-
 Trimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-49-8
 , 4-[2-[[[3-(3-Aminophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-50-1, 4-[2-[[[4-(3-Aminophenyl)phenyl)methyl]amino]pyrimidi-
 n-4-yl]benzamide 403807-51-2, 4-[2-[[[3-(6-
 Quinolylloxy)propyl]amino]pyrimidin-4-yl]benzamide 403807-56-7,
 Ethyl 4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-
 yl]benzoate 403807-57-8, N-Benzyl-4-[2-[[2-[[2-
 pyridyl]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403807-60-3
 , 4-[2-[[[3-(3-Methoxyphenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-62-5, 4-[2-[[3-(2,4-Dichlorophenoxy)propyl]amino]pyrimidin-
 4-yl]benzamide 403807-63-6, 4-[2-[[[3-(3,4-
 Dichlorophenoxy)propyl]amino]pyrimidin-4-yl]benzamide 403807-64-7
 , 4-[2-[[[3-(3-Phenylphenoxy)propyl]amino]pyrimidin-4-yl]benzamide
 403807-65-8, 4-[2-[[[3-[3-(Methylamino)methyl]phenyl]phenyl]methy-
 l]amino]pyrimidin-4-yl]benzamide 403807-68-1,
 4-[2-[[[3-(3-Bromophenoxy)propyl]amino]pyrimidin-4-yl]benzamide
 403807-77-2, N-(2-Methoxyethyl)-4-[2-[[2-[[5-nitro-2-
 pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403807-78-3, 4-[2-[[[3-[3-(Acetylamino)phenyl]phenyl]methyl]amino]
 pyrimidin-4-yl]benzamide 403807-79-4, 4-[2-[[[3,5-

Bis(trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-83-0, 4-[2-[[[3-[3-(Trifluoromethyl)phenyl]phenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-90-9, N-(Oxolan-2-ylmethyl)-4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403807-93-2, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-benzylcarboxamide 403807-94-3, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(3-pyridylmethyl)carboxamide 403807-99-8, N-(2-Thienylmethyl)-4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-03-7, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(4-piperidylmethyl)carboxamide 403808-07-1, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(2-phenylethyl)carboxamide 403808-08-2, N-[(3-Methylphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-11-7, [4-[2-[[2-[[6-Amino-5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-benzylcarboxamide 403808-12-8, N-[(5-Methylpyrazin-2-yl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-13-9, N-[(3-Fluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-15-1, N-[(4-Fluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-16-2, [4-[2-[[3-Bromophenyl)methyl]amino]pyrimidin-4-yl]phenyl]-N-[(3-methylphenyl)methyl]carboxamide 403808-18-4, N-(3-Imidazolylpropyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-19-5 403808-21-9, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(2-phenylcyclopropyl)carboxamide 403808-22-0, N-[(4-Methoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-26-4, N-[(3-Chlorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-27-5, N-[(3,4-Difluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-30-0, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-[(3-nitrophenyl)methyl]carboxamide 403808-32-2, N-[(3-Bromophenyl)methyl]-4-[2-[[2-(3-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-33-3, N-(Naphthylmethyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-37-7, N-[(3,4-Dimethoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-38-8, N-[(2,3-Dimethoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-40-2, N-[(3-Bromophenyl)methyl]-4-[2-[[2-[[6-methoxy-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-41-3 403808-42-4, N-[(3,5-Dichlorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-43-5 403808-46-8 403808-48-0, N-[(3-Bromophenyl)methyl]-4-[2-[[2-[[4-nitrophenyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-49-1, N-[(3-Bromophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-50-4, N-[(4-Bromophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-51-5 403808-52-6, N-[2-(2,4-Dichlorophenyl)ethyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-53-7, N-[(3-Bromophenyl)methyl]-4-[2-


[[2-(2-quinolylamino)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403808-55-9, N-(2,2-Diphenylethyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403808-56-0 403808-58-2 403808-59-3,
 N-[(3-Iodophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403808-97-9, 4-[2-[(2-Phenoxyethyl)amino]pyrimidin-4-yl]benzamide
 403809-14-3, 4-[2-[[2-(2-Pyridyl)ethyl]amino]pyrimidin-4-yl]benzamide 403809-15-4, 4-[2-[(2-Phenylpropyl)amino]pyrimidin-4-yl]benzamide 403809-16-5 403809-17-6,
 4-[2-[[2-[[5-Cyano-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]benzamide
 403809-19-8, 4-[2-[[3-(4-Nitroimidazolyl)propyl]amino]pyrimidin-4-yl]benzamide 403809-20-1, 4-[2-[[2-[(4-Amino-5-cyanopyrimidin-2-yl)amino]ethyl]amino]pyrimidin-4-yl]benzamide 403809-22-3,
 4-[2-[[2-(2,5-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide
 403809-23-4, 4-[2-[[2-(2,3-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide 403809-24-5, 4-[2-[[3-(4-Methoxyphenoxy)propyl]amino]pyrimidin-4-yl]benzamide 403809-25-6
 , 4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]benzamide
 403809-27-8, 4-[2-[[3-(4,5-Dichloroimidazolyl)propyl]amino]pyrimidin-4-yl]benzamide 403809-28-9, 4-[2-[[2-[[5-(Aminothioxomethyl)-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]benzamide 403809-29-0
 , 4-[2-[[3-[[5-Nitro-2-pyridyl]amino]propyl]amino]pyrimidin-4-yl]benzamide
 403809-30-3, 4-[2-[[3-(4-Phenylimidazolyl)propyl]amino]pyrimidin-4-yl]benzamide 403809-31-4 403809-32-5
 403809-33-6, 4-[2-[[2-[[5-(Trifluoromethyl)-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]benzamide 403809-37-0,
 4-[2-[[3-[3-(Trifluoromethyl)phenoxy]propyl]amino]pyrimidin-4-yl]benzamide
 403809-51-8 403809-92-7, N-[(3-Bromophenyl)methyl]-4-[2-[[2-(pyrimidin-2-ylamino)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403810-07-1 403810-50-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)


RN 403806-71-3 CAPLUS

CN Benzamide, 4-[2-[(4-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-72-4 CAPLUS

CN Benzamide, 4-[2-[(1H-imidazol-4-yl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-74-6 CAPLUS

CN Benzamide, 4-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-75-7 CAPLUS

CN Benzamide, 4-[2-[[4-(3-aminophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-76-8 CAPLUS

CN Benzamide, 4-[2-[[4-(4-aminophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-78-0 CAPLUS

CN Benzamide, 4-[2-[[5-(3-methylpyrazin-2-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-80-4 CAPLUS

CN Benzamide, 4-[2-[[4-(4-cyanophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-81-5 CAPLUS

CN Benzamide, 4-[2-[[3-(4-cyanophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-82-6 CAPLUS

CN Benzamide, 4-[2-[[3-(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-83-7 CAPLUS

CN Benzamide, 4-[2-[[2-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-87-1 CAPLUS

CN Benzamide, 4-[2-[[[3-(4-aminobenzamido)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-92-8 CAPLUS

CN Benzamide, 4-[2-[[[4-(4-aminobenzamido)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-94-0 CAPLUS

CN Benzamide, 4-[2-[[[2-(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-96-2 CAPLUS

CN Benzamide, 4-[2-[[[3-(4-aminobenzamido)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-98-4 CAPLUS

CN Benzamide, 4-[2-[[3-(3-nitrophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-02-3 CAPLUS

CN Benzamide, 4-[2-[[2-(3-chlorophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-03-4 CAPLUS

CN Benzamide, 4-[2-[[1-naphthalenylmethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-10-3 CAPLUS

CN Benzamide, 4-[2-[[3-(3-methylphenoxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-11-4 CAPLUS

CN Benzamide, 4-[2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-12-5 CAPLUS

CN Benzamide, 4-[2-[[2-(4-nitrophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-13-6 CAPLUS

CN Benzamide, 4-[2-[[2-(2,6-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-14-7 CAPLUS

CN Benzamide, 4-[2-[[2-(3,4-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-19-2 CAPLUS

CN Benzamide, 4-[2-[[[3-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-20-5 CAPLUS

CN Benzamide, 4-[2-[[[4-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-21-6 CAPLUS

CN Benzamide, 4-[2-[[[3,5-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-23-8 CAPLUS

CN Benzamide, 4-[2-[[[2,4-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-27-2 CAPLUS

CN Benzamide, 4-[2-[[3-(3-methoxyphenoxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 403807-32-9 CAPLUS

CN Benzamide, 4-[2-[[3-[4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-33-0 CAPLUS

CN Benzamide, 4-[2-[[3-[4-(3-methoxyphenyl)-1H-imidazol-1-yl]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-36-3 CAPLUS

CN Benzamide, 4-[2-[[3-(4-chlorophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 403807-37-4 CAPLUS

CN Benzamide, 4-[2-[[3-(4-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)




RN 403807-38-5 CAPLUS

CN Benzamide, 4-[2-[[3-(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-39-6 CAPLUS

CN Benzamide, 4-[2-[[3-(3-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)




RN 403807-43-2 CAPLUS

CN Benzamide, 4-[2-[[2-(2-benzothiazolylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-46-5 CAPLUS

CN Benzamide, 4-[2-[(2,2-diphenylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-47-6 CAPLUS

CN Benzamide, 4-[2-[[3,4,5-trimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-49-8 CAPLUS

CN Benzamide, 4-[2-[[3'-amino[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-50-1 CAPLUS

CN Benzamide, 4-[2-[[3'-(4-aminobenzyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-51-2 CAPLUS

CN Benzamide, 4-[2-[[3-(6-quinolinylloxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-56-7 CAPLUS

CN Benzoic acid, 4-[2-[[2-[[5-nitro-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403807-57-8 CAPLUS

CN Benzamide, N-(phenylmethyl)-4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-60-3 CAPLUS

CN Benzamide, 4-[2-[[3-(3'-methoxy[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-62-5 CAPLUS

CN Benzamide, 4-[2-[[3-(2,4-dichlorophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-63-6 CAPLUS


CN Benzamide, 4-[2-[[3-(3,4-dichlorophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-64-7 CAPLUS
 CN Benzamide, 4-[2-[[3-([1,1'-biphenyl]-3-yloxy)propyl]amino]-4-pyrimidinyl]-
 (9CI) (CA INDEX NAME)




RN 403807-65-8 CAPLUS
 CN Benzamide, 4-[2-[[[3'-[(methylamino)methyl][1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-68-1 CAPLUS
 CN Benzamide, 4-[2-[[3-(3-bromophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI)
 (CA INDEX NAME)



RN 403807-77-2 CAPLUS
 CN Benzamide, N-(2-methoxyethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-78-3 CAPLUS
 CN Benzamide, 4-[2-[[[3'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-79-4 CAPLUS

CN Benzamide, 4-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-83-0 CAPLUS

CN Benzamide, 4-[2-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-90-9 CAPLUS

CN Benzamide, 4-[2-[[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 403807-93-2 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 403807-94-3 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 403807-99-8 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 403808-03-7 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 403808-07-1 CAPLUS


CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 403808-08-2 CAPLUS

CN Benzamide, N-[(3-methylphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 403808-11-7 CAPLUS


CN Benzamide, 4-[2-[[2-[(6-amino-5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 403808-12-8 CAPLUS

CN Benzamide, N-[(5-methylpyrazinyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 403808-13-9 CAPLUS


CN Benzamide, N-[(3-fluorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-15-1 CAPLUS

CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-16-2 CAPLUS

CN Benzamide, 4-[2-[[[(3-bromophenyl)methyl]amino]-4-pyrimidinyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 403808-18-4 CAPLUS

CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-19-5 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-21-9 CAPLUS


CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 403808-22-0 CAPLUS

CN Benzamide, N-[(4-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 403808-26-4 CAPLUS

CN Benzamide, N-[(3-chlorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-Cl

RN 403808-27-5 CAPLUS


CN Benzamide, N-[(3,4-difluorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-30-0 CAPLUS

CN Benzamide, N-[(3-nitrophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-NO2


RN 403808-32-2 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-33-3 CAPLUS

CN Benzamide, N-(1-naphthalenylmethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-37-7 CAPLUS

CN Benzamide, N-[(3,4-dimethoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B


—OMe

RN 403808-38-8 CAPLUS

CN Benzamide, N-[(2,3-dimethoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-OMe

RN 403808-40-2 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-41-3 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


-CF3

RN 403808-42-4 CAPLUS

CN Benzamide, N-[(3,5-dichlorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-Cl

RN 403808-43-5 CAPLUS

CN Benzamide, N-[(3,4-dichlorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-Cl

RN 403808-46-8 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-48-0 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(4-nitrophenyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br

RN 403808-49-1 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br

RN 403808-50-4 CAPLUS

CN Benzamide, N-[(4-bromophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Br


RN 403808-51-5 CAPLUS

CN Benzamide, N-[[4-(aminosulfonyl)phenyl]methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 403808-52-6 CAPLUS

CN Benzamide, N-[2-(2,4-dichlorophenyl)ethyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 403808-53-7 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Br

RN 403808-55-9 CAPLUS


CN Benzamide, N-(2,2-diphenylethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-56-0 CAPLUS

CN Benzamide, 4-[2-[[2-[(6-amino-5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br

RN 403808-58-2 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[[5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br


RN 403808-59-3 CAPLUS

CN Benzamide, N-[(3-iodophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-97-9 CAPLUS

CN Benzamide, 4-[2-[(2-phenoxyethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-14-3 CAPLUS

CN Benzamide, 4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-15-4 CAPLUS

CN Benzamide, 4-[2-[(2-phenylpropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-16-5 CAPLUS

CN Benzamide, 4-[2-[[2-(2-pyrimidinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-17-6 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-19-8 CAPLUS

CN Benzamide, 4-[2-[[3-(4-nitro-1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-20-1 CAPLUS

CN Benzamide, 4-[2-[[2-[(4-amino-5-cyano-2-pyrimidinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-22-3 CAPLUS

CN Benzamide, 4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 403809-23-4 CAPLUS

CN Benzamide, 4-[2-[[2-(2,3-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 403809-24-5 CAPLUS

CN Benzamide, 4-[2-[[3-(4-methoxyphenoxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 403809-25-6 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-27-8 CAPLUS

CN Benzamide, 4-[2-[[3-(4,5-dichloro-1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-28-9 CAPLUS

CN Benzamide, 4-[2-[[2-[[5-(aminothioxomethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403809-29-0 CAPLUS


CN Benzamide, 4-[2-[[3-[(5-nitro-2-pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-30-3 CAPLUS

CN Benzamide, 4-[2-[[3-(4-phenyl-1H-imidazol-1-yl)propyl]amino]-4-

pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-31-4 CAPLUS

CN Benzamide, 4-[2-[[3-(1-naphthalenyloxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 403809-32-5 CAPLUS

CN Benzamide, 4-[2-[[3-(5,6-dimethyl-1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-33-6 CAPLUS

CN Benzamide, 4-[2-[[2-[[5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-37-0 CAPLUS

CN Benzamide, 4-[2-[[3-[3-(trifluoromethyl)phenoxy]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-51-8 CAPLUS

CN Benzamide, 4-[2-[[3-(5,6-dichloro-1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-92-7 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2-pyrimidinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403810-07-1 CAPLUS

CN Benzamide, 4-[2-[[2-[(4-amino-5-cyano-2-pyrimidinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 403810-50-4 CAPLUS

CN Benzamide, 4-[2-[[2-(2-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



L8 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:449662 CAPLUS
 DN 137:33310
 TI Preparation of anilinopyrimidines as IKK inhibitors
 IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.;
 Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
 PA Signal Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 194 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|--|----------|-----------------|----------|
| PI | WO 2002046171 | A2 | 20020613 | WO 2001-US46403 | 20011205 |
| | WO 2002046171 | A3 | 20030123 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2003203926 | A1 | 20031030 | US 2001-4642 | 20011204 |
| | CA 2431160 | AA | 20020613 | CA 2001-2431160 | 20011205 |
| | AU 2002020195 | A5 | 20020618 | AU 2002-20195 | 20011205 |
| | EP 1349841 | A2 | 20031008 | EP 2001-999564 | 20011205 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | JP 2004523497 | T2 | 20040805 | JP 2002-547910 | 20011205 |
| PRAI | US 2000-251816P | P | 20001206 | | |
| | WO 2001-US46403 | W | 20011205 | | |
| OS | MARPAT 137:33310 | | | | |

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of $\leq 1 \mu\text{M}$ in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.


IT 434945-24-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anilinopyrimidines as IKK inhibitors)

RN 434945-24-1 CAPLUS

CN Benzoic acid, 4-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]- (9CI)
 (CA INDEX NAME)




IT 434950-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of anilinopyrimidines as IKK inhibitors)

RN 434950-55-7 CAPLUS

CN Benzoic acid, 4-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:449661 CAPLUS
 DN 137:33309
 TI Preparation of anilinopyrimidines as JNK pathway inhibitors
 IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.;
 Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
 PA Signal Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 199 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002046170 | A2 | 20020613 | WO 2001-US46402 | 20011205 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2430966 | AA | 20020613 | CA 2001-2430966 | 20011205 |
| | AU 2002027214 | A5 | 20020618 | AU 2002-27214 | 20011205 |
| | EP 1349840 | A2 | 20031008 | EP 2001-996103 | 20011205 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2004534728 | T2 | 20041118 | JP 2002-547909 | 20011205 |
| PRAI | US 2000-251904P | P | 20001206 | | |
| | WO 2001-US46402 | W | 20011205 | | |

OS MARPAT 137:33309

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of $\leq 10 \mu\text{M}$ in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.


IT 434945-24-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anilinopyrimidines as JNK pathway inhibitors)

RN 434945-24-1 CAPLUS

CN Benzoic acid, 4-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]- (9CI)
 (CA INDEX NAME)




IT 434950-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of anilinopyrimidines as JNK pathway inhibitors)

RN 434950-55-7 CAPLUS

CN Benzoic acid, 4-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:185092 CAPLUS
 DN 136:247598
 TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
 IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manoj; Levine, Barry H.
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 268 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2002020495 | A2 | 20020314 | WO 2001-US42081 | 20010906 |
| | WO 2002020495 | A3 | 20020620 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2001095026 | A5 | 20020322 | AU 2001-95026 | 20010906 |
| | EP 1317433 | A2 | 20030611 | EP 2001-975734 | 20010906 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2004514656 | T2 | 20040520 | JP 2002-525117 | 20010906 |
| PRAI | US 2000-230480P | P | 20000906 | | |
| | WO 2001-US42081 | W | 20010906 | | |

OS MARPAT 136:247598

AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidiny, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidiny, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3 β in a cell free assay with IC50 values of < 1 μ M. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar


disorder, immunodeficiency, or cancer (no data).

IT 252904-09-9P, Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-[(5-nitro-2-pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- 252904-11-3P, Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-13-5P, Benzamide, N-[(3-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-31-7P, Benzamide, 4-[2-[[2-(2-pyridinylamino)ethyl]amino]-4-pyrimidinyl]- 252904-32-8P, Benzamide, 4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- 252904-33-9P, Benzamide, 4-[2-[[2-[(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-34-0P, Benzamide, 4-[2-[[3-(1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- 252904-35-1P, Benzamide, 4-[2-[[3-(2-naphthalenyloxy)propyl]amino]-4-pyrimidinyl]- 252904-36-2P, Benzenepropanamide, α -[[4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]benzoyl]amino]-, (α S)-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)


RN 252904-09-9 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-[(5-nitro-2-pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 252904-11-3 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-13-5 CAPLUS


CN Benzamide, N-[(3-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

— OMe

RN 252904-31-7 CAPLUS


CN Benzamide, 4-[2-[[2-(2-pyridinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 252904-32-8 CAPLUS


CN Benzamide, 4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 252904-33-9 CAPLUS


CN Benzamide, 4-[2-[[2-[(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-34-0 CAPLUS

CN Benzamide, 4-[2-[[3-(1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)


RN 252904-35-1 CAPLUS

CN Benzamide, 4-[2-[[3-(2-naphthalenyloxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 252904-36-2 CAPLUS

CN Benzenepropanamide, α-[[4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 403806-71-3, 4-[2-[[4-Pyridylmethyl]amino]pyrimidin-4-yl]benzamide
403806-72-4 403806-74-6, 4-[2-[[3-

Methylphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-75-7,
 4-[2-[[[(4-Aminophenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403806-76-8, 4-[2-[[[(5-Methylpyrazin-2-yl)methyl]amino]pyrimidin-4-
 yl]benzamide 403806-78-0, 4-[2-[[[(3-Imidazolylpropyl)amino]pyrimi
 din-4-yl]benzamide 403806-80-4, 4-[2-[[[(4-
 Cyanophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-81-5,
 4-[2-[[[(3-Methoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403806-82-6, 4-[2-[[[(4-Methoxyphenyl)methyl]amino]pyrimidin-4-
 yl]benzamide 403806-83-7, 4-[2-[[2-(4-
 Fluorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide 403806-87-1,
 4-[2-[[[(3-Chlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403806-92-8, 4-[2-[[[(4-Phenylbutyl)amino]pyrimidin-4-yl]benzamide
 403806-94-0, 4-[2-[[2-(3-Methoxyphenyl)ethyl]amino]pyrimidin-4-
 yl]benzamide 403806-96-2, 4-[2-[[[(3-Phenoxypropyl)amino]pyrimidin-
 4-yl]benzamide 403806-98-4, 4-[2-[[[(3-
 Nitrophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-02-3,
 4-[2-[[2-(3-Chlorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide
 403807-03-4, 4-[2-[[[(Naphthylmethyl)amino]pyrimidin-4-yl]benzamide
 403807-10-3, 4-[2-[[[(3-(3-Methylphenoxy)propyl)amino]pyrimidin-4-
 yl]benzamide 403807-11-4, 4-[2-[[2-(2H-Benzo[3,4-d]-1,3-dioxolan-
 5-yl)ethyl]amino]pyrimidin-4-yl]benzamide 403807-12-5,
 4-[2-[[2-(4-Nitrophenyl)ethyl]amino]pyrimidin-4-yl]benzamide
 403807-13-6, 4-[2-[[[(2,6-Dimethoxyphenyl)methyl]amino]pyrimidin-4-
 yl]benzamide 403807-14-7, 4-[2-[[[(3,4-
 Dimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-19-2
 , 4-[2-[[[(3-(Trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-20-5, 4-[2-[[[(4-(Trifluoromethyl)phenyl)methyl]amino]pyrimi
 din-4-yl]benzamide 403807-21-6, 4-[2-[[[(3,5-
 Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-23-8
 , 4-[2-[[[(2,4-Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-27-2, 4-[2-[[[(3-(3-Methoxyphenoxy)propyl)amino]pyrimidin-4-
 yl]benzamide 403807-32-9, 4-[2-[[[(3-[4-(2,4-
 Dichlorophenyl)imidazolyl]propyl]amino]pyrimidin-4-yl]benzamide
 403807-33-0, 4-[2-[[[(3-[4-(3-Methoxyphenyl)imidazolyl]propyl]amino]
 pyrimidin-4-yl]benzamide 403807-36-3, 4-[2-[[[(3-(4-
 Chlorophenoxy)propyl]amino]pyrimidin-4-yl]benzamide 403807-37-4,
 4-[2-[[[(4-Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-38-5, 4-[2-[[[(4-(4-Fluorophenyl)phenyl)methyl]amino]pyrimid
 in-4-yl]benzamide 403807-39-6, 4-[2-[[[(3-
 Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-43-2,
 4-[2-[[2-(Benzothiazol-2-ylamino)ethyl]amino]pyrimidin-4-yl]benzamide
 403807-46-5, 4-[2-[[[(2,2-Diphenylethyl)amino]pyrimidin-4-
 yl]benzamide 403807-47-6, 4-[2-[[[(3,4,5-
 Trimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-49-8
 , 4-[2-[[[(3-(3-Aminophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-50-1, 4-[2-[[[(4-(3-Aminophenyl)phenyl)methyl]amino]pyrimidi
 n-4-yl]benzamide 403807-51-2, 4-[2-[[[(3-(6-
 Quinolylloxy)propyl]amino]pyrimidin-4-yl]benzamide 403807-56-7,
 Ethyl 4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-
 yl]benzoate 403807-57-8, N-Benzyl-4-[2-[[2-[[2-
 pyridyl]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403807-60-3
 , 4-[2-[[[(3-(3-Methoxyphenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide
 403807-62-5, 4-[2-[[[(3-(2,4-Dichlorophenoxy)propyl]amino]pyrimidin-
 4-yl]benzamide 403807-63-6, 4-[2-[[[(3-(3,4-
 Dichlorophenoxy)propyl]amino]pyrimidin-4-yl]benzamide 403807-64-7
 , 4-[2-[[[(3-(3-Phenylphenoxy)propyl]amino]pyrimidin-4-yl]benzamide
 403807-65-8, 4-[2-[[[(3-[3-(Methylamino)methyl]phenyl]phenyl)methy
 l]amino]pyrimidin-4-yl]benzamide 403807-68-1,

4-[2-[[3-(3-Bromophenoxy)propyl]amino]pyrimidin-4-yl]benzamide
403807-77-2, N-(2-Methoxyethyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403807-78-3, 4-[2-[[[3-(3-Acetylamino)phenyl]phenyl]methyl]amino]pyrimidin-4-yl]benzamide **403807-79-4**, 4-[2-[[[3,5-Bis(trifluoromethyl)phenyl]methyl]amino]pyrimidin-4-yl]benzamide
403807-83-0, 4-[2-[[[3-(3-Trifluoromethyl)phenyl]phenyl]methyl]amino]pyrimidin-4-yl]benzamide **403807-90-9**, N-(Oxolan-2-ylmethyl)-4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403807-93-2**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-benzylcarboxamide
403807-94-3, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(3-pyridylmethyl)carboxamide **403807-99-8**, N-(2-Thienylmethyl)-4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-03-7**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(4-piperidylmethyl)carboxamide **403808-07-1**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(2-phenylethyl)carboxamide **403808-08-2**, N-[(3-Methylphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-11-7**, [4-[2-[[2-[[6-Amino-5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-benzylcarboxamide
403808-12-8, N-[(5-Methylpyrazin-2-yl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-13-9, N-[(3-Fluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-15-1, N-[(4-Fluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-16-2, [4-[2-[[[3-Bromophenyl]methyl]amino]pyrimidin-4-yl]phenyl]-N-[(3-methylphenyl)methyl]carboxamide **403808-18-4**, N-(3-Imidazolylpropyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-19-5** **403808-21-9**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(2-phenylcyclopropyl)carboxamide **403808-22-0**, N-[(4-Methoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-26-4, N-[(3-Chlorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-27-5, N-[(3,4-Difluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-30-0, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-[(3-nitrophenyl)methyl]carboxamide **403808-32-2**, N-[(3-Bromophenyl)methyl]-4-[2-[[2-[(3-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-33-3**, N-(Naphthylmethyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-37-7, N-[(3,4-Dimethoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-38-8, N-[(2,3-Dimethoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-40-2, N-[(3-Bromophenyl)methyl]-4-[2-[[2-[[6-methoxy-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-41-3 **403808-42-4**, N-[(3,5-Dichlorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-43-5** **403808-46-8**
403808-48-0, N-[(3-Bromophenyl)methyl]-4-[2-[[2-[(4-nitrophenyl)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
403808-49-1, N-[(3-Bromophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide


403808-50-4, N-[(4-Bromophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403808-51-5 403808-52-6, N-[2-(2,4-Dichlorophenyl)ethyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide 403808-53-7, N-[(3-Bromophenyl)methyl]-4-[2-[[2-(2-quinolylamino)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403808-55-9, N-(2,2-Diphenylethyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403808-56-0 403808-58-2 403808-59-3, N-[(3-Iodophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403808-97-9, 4-[2-[[2-(Phenoxyethyl)amino]pyrimidin-4-yl]benzamide
 403809-14-3, 4-[2-[[2-(2-Pyridyl)ethyl]amino]pyrimidin-4-yl]benzamide 403809-15-4, 4-[2-[[2-(Phenylpropyl)amino]pyrimidin-4-yl]benzamide 403809-16-5 403809-17-6, 4-[2-[[2-[[5-Cyano-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]benzamide
 403809-19-8, 4-[2-[[3-(4-Nitroimidazolyl)propyl]amino]pyrimidin-4-yl]benzamide 403809-20-1, 4-[2-[[2-[[4-Amino-5-cyanopyrimidin-2-yl]amino]ethyl]amino]pyrimidin-4-yl]benzamide 403809-22-3, 4-[2-[[2-(2,5-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide
 403809-23-4, 4-[2-[[2-(2,3-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide 403809-24-5, 4-[2-[[3-(4-Methoxyphenoxy)propyl]amino]pyrimidin-4-yl]benzamide 403809-25-6, 4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]benzamide
 403809-27-8, 4-[2-[[3-(4,5-Dichloroimidazolyl)propyl]amino]pyrimidin-4-yl]benzamide 403809-28-9, 4-[2-[[2-[[5-(Aminothioxomethyl)-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]benzamide 403809-29-0, 4-[2-[[3-[[5-Nitro-2-pyridyl]amino]propyl]amino]pyrimidin-4-yl]benzamide
 403809-30-3, 4-[2-[[3-(4-Phenylimidazolyl)propyl]amino]pyrimidin-4-yl]benzamide 403809-31-4 403809-32-5 403809-33-6, 4-[2-[[2-[[5-(Trifluoromethyl)-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]benzamide 403809-37-0, 4-[2-[[3-[3-(Trifluoromethyl)phenoxy]propyl]amino]pyrimidin-4-yl]benzamide
 403809-51-8 403809-92-7, N-[(3-Bromophenyl)methyl]-4-[2-[[2-(pyrimidin-2-ylamino)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide
 403810-07-1 403810-50-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)

RN 403806-71-3 CAPLUS


CN Benzamide, 4-[2-[(4-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-72-4 CAPLUS

CN Benzamide, 4-[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 403806-74-6 CAPLUS

CN Benzamide, 4-[2-[[[3-methylphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)

RN 403806-75-7 CAPLUS


CN Benzamide, 4-[2-[[[4-aminophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)

RN 403806-76-8 CAPLUS

CN Benzamide, 4-[2-[[[5-methylpyrazinyl)methyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 403806-78-0 CAPLUS

CN Benzamide, 4-[2-[[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 403806-80-4 CAPLUS

CN Benzamide, 4-[2-[[[(4-cyanophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-81-5 CAPLUS

CN Benzamide, 4-[2-[[[(3-methoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-82-6 CAPLUS

CN Benzamide, 4-[2-[[[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-83-7 CAPLUS

CN Benzamide, 4-[2-[[[2-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-87-1 CAPLUS

CN Benzamide, 4-[2-[[4-(3-chlorophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-92-8 CAPLUS

CN Benzamide, 4-[2-[[4-(4-phenylbutyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-94-0 CAPLUS

CN Benzamide, 4-[2-[[2-(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-96-2 CAPLUS

CN Benzamide, 4-[2-[[3-phenoxypropyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-98-4 CAPLUS

CN Benzamide, 4-[2-[[3-(3-nitrophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-02-3 CAPLUS

CN Benzamide, 4-[2-[[2-(3-chlorophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-03-4 CAPLUS

CN Benzamide, 4-[2-[[1-(naphthalenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-10-3 CAPLUS

CN Benzamide, 4-[2-[[3-(3-methylphenoxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-11-4 CAPLUS

CN Benzamide, 4-[2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-12-5 CAPLUS

CN Benzamide, 4-[2-[[2-(4-nitrophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-13-6 CAPLUS

CN Benzamide, 4-[2-[[2-(2,6-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-14-7 CAPLUS

CN Benzamide, 4-[2-[[2-(3,4-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-19-2 CAPLUS

CN Benzamide, 4-[2-[[[3-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-20-5 CAPLUS

CN Benzamide, 4-[2-[[[4-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-21-6 CAPLUS

CN Benzamide, 4-[2-[[[3,5-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-23-8 CAPLUS

CN Benzamide, 4-[2-[[[2,4-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-27-2 CAPLUS

CN Benzamide, 4-[2-[[3-(3-methoxyphenoxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 403807-32-9 CAPLUS

CN Benzamide, 4-[2-[[3-[4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-33-0 CAPLUS

CN Benzamide, 4-[2-[[3-[4-(3-methoxyphenyl)-1H-imidazol-1-yl]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-36-3 CAPLUS

CN Benzamide, 4-[2-[[3-(4-chlorophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 403807-37-4 CAPLUS

CN Benzamide, 4-[2-[[[4-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)




RN 403807-38-5 CAPLUS

CN Benzamide, 4-[2-[[[4'-fluoro[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-39-6 CAPLUS

CN Benzamide, 4-[2-[[[3-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)




RN 403807-43-2 CAPLUS

CN Benzamide, 4-[2-[[2-(2-benzothiazolylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-46-5 CAPLUS

CN Benzamide, 4-[2-[(2,2-diphenylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-47-6 CAPLUS

CN Benzamide, 4-[2-[[3,4,5-trimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-49-8 CAPLUS

CN Benzamide, 4-[2-[[3'-amino[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-50-1 CAPLUS

CN Benzamide, 4-[2-[[3'-(4-aminobenzyl)amino]-4-pyrimidinyl]-4-aminobenzamide]benzoic acid (9CI) (CA INDEX NAME)




RN 403807-51-2 CAPLUS

CN Benzamide, 4-[2-[[3-(6-quinolinyl)propyl]amino]-4-pyrimidinyl]benzoic acid (9CI) (CA INDEX NAME)




RN 403807-56-7 CAPLUS

CN Benzoic acid, 4-[2-[[2-((5-nitro-2-pyridinyl)amino)ethyl]amino]-4-pyrimidinyl]benzoic acid ethyl ester (9CI) (CA INDEX NAME)




RN 403807-57-8 CAPLUS

CN Benzamide, N-(phenylmethyl)-4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]benzoic acid ethyl ester (9CI) (CA INDEX NAME)




RN 403807-60-3 CAPLUS

CN Benzamide, 4-[2-[[3-(2,4-dichlorophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-62-5 CAPLUS

CN Benzamide, 4-[2-[[3-(3-methoxyphenyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-63-6 CAPLUS

CN Benzamide, 4-[2-[[3-(3,4-dichlorophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-64-7 CAPLUS


CN Benzamide, 4-[2-[[3-([1,1'-biphenyl]-3-yloxy)propyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)

RN 403807-65-8 CAPLUS

CN Benzamide, 4-[2-[[[3'-[(methylamino)methyl][1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-68-1 CAPLUS

CN Benzamide, 4-[2-[[3-(3-bromophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 403807-77-2 CAPLUS

CN Benzamide, N-(2-methoxyethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-78-3 CAPLUS

CN Benzamide, 4-[2-[[[3'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-79-4 CAPLUS

CN Benzamide, 4-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-83-0 CAPLUS

CN Benzamide, 4-[2-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-90-9 CAPLUS

CN Benzamide, 4-[2-[[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(tetrahydro-2-furanyl)methyl]pyrimidin-2-amine (9CI) (CA INDEX NAME)




RN 403807-93-2 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 403807-94-3 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 403807-99-8 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 403808-03-7 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 403808-07-1 CAPLUS


CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 403808-08-2 CAPLUS

CN Benzamide, N-[(3-methylphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Me

RN 403808-11-7 CAPLUS


CN Benzamide, 4-[2-[[2-[(6-amino-5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 403808-12-8 CAPLUS

CN Benzamide, N-[(5-methylpyrazinyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Me

RN 403808-13-9 CAPLUS


CN Benzamide, N-[(3-fluorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-15-1 CAPLUS

CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-16-2 CAPLUS

CN Benzamide, 4-[2-[[[3-bromophenyl)methyl]amino]-4-pyrimidinyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 403808-18-4 CAPLUS


CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-19-5 CAPLUS
 CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-21-9 CAPLUS
 CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 403808-22-0 CAPLUS
 CN Benzamide, N-[(4-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 403808-26-4 CAPLUS
 CN Benzamide, N-[(3-chlorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl

RN 403808-27-5 CAPLUS


CN Benzamide, N-[(3,4-difluorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-30-0 CAPLUS

CN Benzamide, N-[(3-nitrophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NO₂


RN 403808-32-2 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-33-3 CAPLUS

CN Benzamide, N-(1-naphthalenylmethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-37-7 CAPLUS

CN Benzamide, N-[(3,4-dimethoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B


—OMe

RN 403808-38-8 CAPLUS

CN Benzamide, N-[(2,3-dimethoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 403808-40-2 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-41-3 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃

RN 403808-42-4 CAPLUS

CN Benzamide, N-[(3,5-dichlorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




PAGE 1-B

-Cl

RN 403808-43-5 CAPLUS

CN Benzamide, N-[(3,4-dichlorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




PAGE 1-B

-Cl

RN 403808-46-8 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-48-0 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(4-nitrophenyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br

RN 403808-49-1 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br

RN 403808-50-4 CAPLUS

CN Benzamide, N-[(4-bromophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Br


RN 403808-51-5 CAPLUS

CN Benzamide, N-[[4-(aminosulfonyl)phenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 403808-52-6 CAPLUS

CN Benzamide, N-[2-(2,4-dichlorophenyl)ethyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 403808-53-7 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 403808-55-9 CAPLUS


CN Benzamide, N-(2,2-diphenylethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-56-0 CAPLUS

CN Benzamide, 4-[2-[[2-[(6-amino-5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br

RN 403808-58-2 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[[5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Br


RN 403808-59-3 CAPLUS

CN Benzamide, N-[(3-iodophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-97-9 CAPLUS

CN Benzamide, 4-[2-[(2-phenoxyethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-14-3 CAPLUS

CN Benzamide, 4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-15-4 CAPLUS

CN Benzamide, 4-[2-[(2-phenylpropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-16-5 CAPLUS

CN Benzamide, 4-[2-[[2-(2-pyrimidinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-17-6 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-19-8 CAPLUS

CN Benzamide, 4-[2-[[3-(4-nitro-1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-20-1 CAPLUS

CN Benzamide, 4-[2-[[2-[(4-amino-5-cyano-2-pyrimidinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-22-3 CAPLUS

CN Benzamide, 4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]-(9CI) (CA INDEX NAME)




RN 403809-23-4 CAPLUS

CN Benzamide, 4-[2-[[2-(2,3-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]-(9CI) (CA INDEX NAME)




RN 403809-24-5 CAPLUS

CN Benzamide, 4-[2-[[3-(4-methoxyphenoxy)propyl]amino]-4-pyrimidinyl]-(9CI) (CA INDEX NAME)




RN 403809-25-6 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-(9CI) (CA INDEX NAME)




RN 403809-27-8 CAPLUS

CN Benzamide, 4-[2-[[3-(4,5-dichloro-1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-28-9 CAPLUS

CN Benzamide, 4-[2-[[2-[[5-(aminothioxomethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403809-29-0 CAPLUS


CN Benzamide, 4-[2-[[3-[(5-nitro-2-pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-30-3 CAPLUS

CN Benzamide, 4-[2-[[3-(4-phenyl-1H-imidazol-1-yl)propyl]amino]-4-

pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-31-4 CAPLUS

CN Benzamide, 4-[2-[[3-(1-naphthalenyloxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 403809-32-5 CAPLUS

CN Benzamide, 4-[2-[[3-(5,6-dimethyl-1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-33-6 CAPLUS

CN Benzamide, 4-[2-[[2-[[5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-37-0 CAPLUS

CN Benzamide, 4-[2-[[3-[[3-(trifluoromethyl)phenoxy]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-51-8 CAPLUS

CN Benzamide, 4-[2-[[3-[(5,6-dichloro-1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-92-7 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2-pyrimidinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403810-07-1 CAPLUS

CN Benzamide, 4-[2-[[2-[(4-amino-5-cyano-2-pyrimidinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 403810-50-4 CAPLUS

CN Benzamide, 4-[2-[[2-(2-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



L8 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:798080 CAPLUS

DN 135:339258

TI Medicinal compositions promoting bowel movement

IN Yasuda, Masahiro; Harada, Hitoshi; Miyazawa, Shuhei; Kobayashi, Seiichi;
Harada, Kokichi; Hida, Takayuki; Shibata, Hisashi; Yasuda, Nobuyuki;
Asano, Osamu; Kotake, Yoshihiko

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001080893 | A1 | 20011101 | WO 2001-JP3643 | 20010426 |
| | W: AU, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| | AU 2001052606 | A5 | 20011107 | AU 2001-52606 | 20010426 |
| | CA 2407013 | AA | 20021022 | CA 2001-2407013 | 20010426 |
| | EP 1283056 | A1 | 20030212 | EP 2001-925974 | 20010426 |
| | EP 1283056 | B1 | 20041215 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | |
| | AT 284712 | E | 20050115 | AT 2001-925974 | 20010426 |
| | NZ 521633 | A | 20050128 | NZ 2001-521633 | 20010426 |
| | EP 1510222 | A2 | 20050302 | EP 2004-24423 | 20010426 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | |
| | ZA 2002007744 | A | 20030926 | ZA 2002-7744 | 20020926 |
| | US 2003171383 | A1 | 20030911 | US 2002-257091 | 20021009 |
| | NO 2002005116 | A | 20021223 | NO 2002-5116 | 20021024 |
| PRAI | JP 2000-126489 | A | 20000426 | | |
| | JP 2000-220124 | A | 20000721 | | |
| | EP 2001-925974 | A3 | 20010426 | | |
| | WO 2001-JP3643 | W | 20010426 | | |

OS MARPAT 135:339258

AB Drugs having a gentle and potent effect of promoting the bowel movement without causing diarrhea. Namely, bowel movement promoters which contain compds. having an adenosine A2 receptor antagonism (preferably compds. having an adenosine A2b receptor antagonism) or salts thereof.


IT 371230-87-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(medicinal compns. containing adenosine A2 and A2b receptor antagonists for promoting bowel movement)

RN 371230-87-4 CAPLUS

CN Benzoic acid, 3-[2-amino-5-(4-pyridinyl)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:911230 CAPLUS
 DN 134:71598
 TI Preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFR kinase.
 IN Batchelor, Mark James; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 PA Celltech Chiroscience Limited, UK
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2000078731 | A1 | 20001228 | WO 2000-GB2382 | 20000619 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6579983 | B1 | 20030617 | US 2000-596952 | 20000616 |
| | CA 2375182 | AA | 20001228 | CA 2000-2375182 | 20000619 |
| | BR 2000011770 | A | 20020305 | BR 2000-11770 | 20000619 |
| | EP 1187816 | A1 | 20020320 | EP 2000-940569 | 20000619 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | DE 10084704 | T | 20020529 | DE 2000-10084704 | 20000619 |
| | GB 2369360 | A1 | 20020529 | GB 2001-30563 | 20000619 |
| | JP 2003502406 | T2 | 20030121 | JP 2001-504897 | 20000619 |
| | ES 2188429 | A1 | 20030616 | ES 2001-50085 | 20000619 |
| | ES 2188429 | B2 | 20050616 | | |
| | AU 778533 | B2 | 20041209 | AU 2000-55488 | 20000619 |
| | BG 106116 | A | 20020731 | BG 2001-106116 | 20011119 |
| | ZA 2001009841 | A | 20020429 | ZA 2001-9841 | 20011129 |
| | NO 2001006162 | A | 20020218 | NO 2001-6162 | 20011217 |
| | US 2002147339 | A1 | 20021010 | US 2002-151518 | 20020520 |
| | HK 1048815 | A1 | 20050429 | HK 2003-101022 | 20030212 |
| | US 2004180914 | A1 | 20040916 | US 2004-812293 | 20040329 |
| PRAI | GB 1999-14258 | A | 19990618 | | |
| | US 2000-596952 | A1 | 20000616 | | |
| | WO 2000-GB2382 | W | 20000619 | | |
| | US 2002-151518 | B1 | 20020520 | | |

OS MARPAT 134:71598

AB Title compds. [I; Ar = (substituted) aryl, heteroaryl; R1 = H, alkyl; R2 = X1R3; X1 = bond, linker atom or group; R3 = (substituted) aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom. group] and the salts, solvates, hydrates and N-oxides thereof, were prepared Thus, 3,4,5-trimethoxyphenylguanidinium nitrate (preparation given), 1-phenyl-2-cyano-3-dimethylaminopropen-1-one, and NaOH were refluxed in EtOH to give 5-cyano-4-phenyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine. I inhibited KDR kinase and FGFR kinase with IC50 ≤ 1 μM.


IT 314267-39-5P 314267-72-6P 314267-74-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFR kinase)


RN 314267-39-5 CAPLUS

CN Benzoic acid, 4-[5-cyano-2-[[4-[2-(1H-imidazol-1-yl)ethyl]phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 314267-72-6 CAPLUS

CN Benzoic acid, 4-[5-cyano-2-[[4-(2-hydroxyethyl)phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 314267-74-8 CAPLUS

CN Benzoic acid, 4-[5-cyano-2-[[3,4,5-trimethoxyphenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 314267-75-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFR kinase)

RN 314267-75-9 CAPLUS

CN Benzoic acid, 4-[5-cyano-2-[[4-[2-[[4-methylphenyl]sulfonyl]oxy]ethyl]phe

nyl)amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:457028 CAPLUS
 DN 133:89545
 TI Substituted (aminoiminomethyl- or aminomethyl)benzoheteroaryl compounds
 useful as anticoagulants
 IN Dankulich, William P.; McGarry, Daniel G.; Burns, Christopher; Gallagher,
 Timothy F.; Volz, Francis A.
 PA Aventis Pharmaceuticals Products Inc., USA
 SO PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2000039087 | A2 | 20000706 | WO 1999-US30623 | 19991222 |
| | WO 2000039087 | A3 | 20001109 | | |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2358047 | AA | 20000706 | CA 1999-2358047 | 19991222 |
| | EP 1140901 | A2 | 20011010 | EP 1999-966560 | 19991222 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| | BR 9916845 | A | 20011030 | BR 1999-16845 | 19991222 |
| | JP 2002533438 | T2 | 20021008 | JP 2000-590999 | 19991222 |
| | EE 200100341 | A | 20021216 | EE 2001-341 | 19991222 |
| | AU 760983 | B2 | 20030529 | AU 2000-22071 | 19991222 |
| | NZ 512548 | A | 20030829 | NZ 1999-512548 | 19991222 |
| | US 6541505 | B1 | 20030401 | US 2000-609103 | 20000630 |
| | NO 2001003142 | A | 20010821 | NO 2001-3142 | 20010622 |
| | US 2003153604 | A1 | 20030814 | US 2003-372499 | 20030224 |
| PRAI | US 1998-113710P | A2 | 19981224 | | |
| | WO 1999-US30623 | W | 19991222 | | |
| | US 2000-609103 | A1 | 20000630 | | |

OS MARPAT 133:89545

AB The invention is directed to (aminoiminomethyl)- or (aminomethyl)-substituted benzoheteroaryl compds. I, which are useful as inhibitors of Factor Xa (no data) [wherein X = O, S, NH or derivs.; L1 = alkylene, alkenylene, alkynylene; L2 = bond, or as given for L1; Q = NH or derivs., O, CO, COO, OCO, NHCO or derivs., S(O)0-2, SO2NH or derivs, etc.; R = H, cycloalkyl, heterocyclyl, aryl, wide range of other cyclic groups; R2, R3 = H; or R2R3 = NH or derivs.]. The invention is also directed to compns. containing the compds., methods for their preparation, and their use, e.g., in

the inhibition of thrombin formation, or for treating a patient suffering from, or subject to, a disease state associated with excess thrombin. Approx. 160 examples were prepared and claimed, and hundreds of intermediates were prepared For instance, 4-(pyrid-3-yl)benzoic acid underwent amidation with 3-cyano-5-(2-aminoethyl)indole using TBTU and DIEA, and the product nitrile was treated with HCl(g) in MeOH followed by NH3 in MeOH, to give the invention compound II.


IT 201232-31-3P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[[2-

(dimethylamino)ethyl]amino]pyrimidin-4-yl]benzamide 281232-40-4P,
 , N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[2-(morpholin-4-yl)ethylamino]pyrimidin-4-yl]benzamide 281232-41-5P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[3-(dimethylamino)propyl]amino]pyrimidin-4-yl]benzamide 281233-85-0P, 4-[2-[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl]benzoic acid
 281233-86-1P, 4-[2-[2-(Dimethylamino)ethyl]amino]pyrimidin-4-yl]benzoic acid trifluoroacetic acid salt 281234-04-6P,
 4-[2-[2-(Morpholin-4-yl)ethyl]amino]pyrimidin-4-yl]benzoic acid 281234-05-7P, 4-[2-[3-(Dimethylamino)propyl]amino]pyrimidin-4-yl]benzoic acid 281234-07-9P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[2-(2-hydroxy-1-(hydroxymethyl)ethyl)amino]pyrimidin-4-yl]benzamide 281234-08-0P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[5-(dimethylamino)pentyl]amino]pyrimidin-4-yl]benzamide 281234-09-1P,
 , N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(5-morpholin-4-ylpentylamino)pyrimidin-4-yl]benzamide 281234-10-4P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(5-piperidin-1-ylpentylamino)pyrimidin-4-yl]benzamide 281234-11-5P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(5-pyrrolidin-1-ylpentylamino)pyrimidin-4-yl]benzamide 281234-18-2P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(6-pyrrolidin-1-ylhexylamino)pyrimidin-4-yl]benzamide 281234-19-3P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(6-piperidin-1-ylhexylamino)pyrimidin-4-yl]benzamide 281234-20-6P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(4-piperidin-1-ylbutylamino)pyrimidin-4-yl]benzamide 281234-21-7P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[4-(diethylamino)butyl]amino]pyrimidin-4-yl]benzamide 281234-22-8P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(6-morpholin-4-ylhexylamino)pyrimidin-4-yl]benzamide 281234-23-9P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[6-(dimethylamino)hexyl]amino]pyrimidin-4-yl]benzamide 281234-24-0P,
 , N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[4-(dimethylamino)butyl]amino]pyrimidin-4-yl]benzamide 281234-25-1P,
 , 4-[2-[2-(Bicyclo[2.2.1]hept-2-yl)amino]pyrimidin-4-yl]-N-[2-(3-cyano-1H-indol-5-yl)ethyl]benzamide 281234-31-9P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(3-hydroxypropylamino)pyrimidin-4-yl]benzamide 281234-36-4P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(2,3-dihydroxypropylamino)pyrimidin-4-yl]benzamide 281234-40-0P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[2-(2-oxoimidazolidin-1-yl)ethyl]amino]pyrimidin-4-yl]benzamide 281234-41-1P,
 N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(3-methoxypropylamino)pyrimidin-4-yl]benzamide 281234-42-2P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(2-hydroxyethylamino)pyrimidin-4-yl]benzamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted (aminoiminomethyl- or aminomethyl)benzoheteroaryl compds. as anticoagulants)


RN 281232-31-3 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[2-(dimethylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281232-40-4 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281232-41-5 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[3-(dimethylamino)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281233-85-0 CAPLUS

CN Benzoic acid, 4-[2-[[2-(dimethylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281233-86-1 CAPLUS

CN Benzoic acid, 4-[2-[[2-(dimethylamino)ethyl]amino]-4-pyrimidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 281233-85-0


CMF C15 H18 N4 O2




CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 281234-04-6 CAPLUS


CN Benzoic acid, 4-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 281234-05-7 CAPLUS

CN Benzoic acid, 4-[2-[[3-(dimethylamino)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 281234-07-9 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-08-0 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[5-(dimethylamino)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-09-1 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[5-(4-morpholinyl)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-10-4 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[5-(1-piperidiny)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-11-5 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[5-(1-pyrrolidiny)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281234-18-2 CAPLUS


CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[6-(1-pyrrolidiny)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281234-19-3 CAPLUS


CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[6-(1-

piperidiny]hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-20-6 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[4-(1-piperidiny]butyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-21-7 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[4-(diethylamino)butyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-22-8 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[6-(4-morpholinyl)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-23-9 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[6-(dimethylamino)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-24-0 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[4-(dimethylamino)butyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-25-1 CAPLUS

CN Benzamide, 4-[2-(bicyclo[2.2.1]hept-2-ylamino)-4-pyrimidinyl]-N-[2-(3-cyano-1H-indol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 281234-31-9 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-36-4 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(2,3-dihydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-40-0 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-41-1 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281234-42-2 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(2-hydroxyethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 281230-73-7P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl]benzamide 281230-82-8P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(2-morpholin-4-ylethylamino)pyrimidin-4-yl]benzamide 281230-83-9P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[3-(dimethylamino)propyl]amino]pyrimidin-4-yl]benzamide 281230-88-4P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]pyrimidin-4-yl]benzamide 281230-89-5P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-(imidazol-1-yl)propylamino)pyrimidin-4-yl]benzamide 281230-91-9P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[2-(diisopropylamino)ethyl]amino]pyrimidin-4-yl]benzamide 281230-92-0P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[2-(dibutylamino)ethyl]amino]pyrimidin-4-yl]benzamide 281230-93-1P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]benzamide 281230-94-2P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[3-(diethylamino)propyl]amino]pyrimidin-4-yl]benzamide 281230-95-3P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-piperidin-1-ylpropylamino)pyrimidin-4-yl]benzamide 281230-97-5P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[5-(dimethylamino)pentyl]amino]pyrimidin-4-yl]benzamide 281230-98-6P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(5-morpholin-4-ylpentylamino)pyrimidin-4-yl]benzamide 281230-99-7P,


N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(5-piperidin-1-ylpentylamino)pyrimidin-4-yl]benzamide 281231-00-3P,
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(5-pyrrolidin-1-ylpentylamino)pyrimidin-4-yl]benzamide 281231-18-3P,
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(6-pyrrolidin-1-ylhexylamino)pyrimidin-4-yl]benzamide 281231-19-4P,
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(6-piperidin-1-ylhexylamino)pyrimidin-4-yl]benzamide 281231-20-7P,
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(4-piperidin-1-ylbutylamino)pyrimidin-4-yl]benzamide 281231-21-8P,
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[4-(diethylamino)butyl]amino]pyrimidin-4-yl]benzamide 281231-22-9P,
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(6-morpholin-4-ylhexylamino)pyrimidin-4-yl]benzamide 281231-23-0P,
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[6-(dimethylamino)hexyl]amino]pyrimidin-4-yl]benzamide 281231-24-1P,
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[4-(dimethylaminobutyl)amino]pyrimidin-4-yl]benzamide 281231-25-2P,
 4-[2-[[Bicyclo[2.2.1]hept-2-yl]amino]pyrimidin-4-yl]-N-[2-(3-carbamimidoyl-1H-indol-5-yl)ethyl]benzamide 281231-31-0P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-hydroxypropylamino)pyrimidin-4-yl]benzamide 281231-36-5P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(2,3-dihydroxypropylamino)pyrimidin-4-yl]benzamide 281231-40-1P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[2-(2-oxoimidazolidin-1-yl)ethyl]amino]pyrimidin-4-yl]benzamide 281231-41-2P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-methoxypropylamino)pyrimidin-4-yl]benzamide 281231-42-3P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[[2-(hydroxyethyl)amino]pyrimidin-4-yl]benzamide 281235-35-6P 281235-42-5P 281235-43-6P 281235-44-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of substituted (aminoiminomethyl- or aminomethyl)benzoheteroaryl compds. as anticoagulants)

RN 281230-73-7 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[2-(dimethylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281230-82-8 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂


RN 281230-83-9 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[3-(dimethylamino)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281230-88-4 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281230-89-5 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281230-91-9 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[2-[bis(1-methylethyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂

RN 281230-92-0 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[2-(dibutylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂


RN 281230-93-1 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281230-94-2 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[3-(diethylamino)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281230-95-3 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[3-(1-piperidiny)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281230-97-5 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[5-(dimethylamino)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281230-98-6 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[5-(4-

morpholinyl)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281230-99-7 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[5-(1-piperidinyl)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-00-3 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[5-(1-pyrrolidinyl)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-18-3 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[6-(1-pyrrolidinyl)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-19-4 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[6-(1-piperidinyl)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-20-7 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[4-(1-piperidinyl)butyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-21-8 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[4-(diethylamino)butyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-22-9 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[6-(4-morpholinyl)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-23-0 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[6-(dimethylamino)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-24-1 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[4-(dimethylamino)butyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-25-2 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-(bicyclo[2.2.1]hept-2-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-31-0 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281231-36-5 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2,3-dihydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281231-40-1 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂


RN 281231-41-2 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281231-42-3 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-hydroxyethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281235-35-6 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[2-(dimethylamino)ethyl]amino]-4-pyrimidinyl]-, tris(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 281230-73-7


CMF C26 H30 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 281235-42-5 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[6-(dimethylamino)hexyl]amino]-4-pyrimidinyl]-, tris(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 281231-23-0


CMF C30 H38 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 281235-43-6 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[4-(dimethylamino)butyl]amino]-4-pyrimidinyl]-, tris(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 281231-24-1


CMF C28 H34 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 281235-44-7 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-(bicyclo[2.2.1]hept-2-ylamino)-4-pyrimidinyl]-, bis(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 281231-25-2


CMF C29 H31 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L8 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:811233 CAPLUS

DN 132:64265

TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors

IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Brown, Sean P.; Goff, Dane; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithry; Renhowe, Paul A.; Seely, Lynn; Subramanian, Sharadha; Wagman, Allan S.; Zhou, Xiaohui A.

PA Chiron Corporation, USA

SO PCT Int. Appl., 262 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9965897 | A1 | 19991223 | WO 1999-US13809 | 19990618 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9949566 | A1 | 20000105 | AU 1999-49566 | 19990618 |
| | EP 1087963 | A1 | 20010404 | EP 1999-933522 | 19990618 |
| | EP 1087963 | B1 | 20040825 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | US 6489344 | B1 | 20021203 | US 1999-336098 | 19990618 |
| | JP 2003527303 | T2 | 20030916 | JP 2000-554722 | 19990618 |
| | AT 274510 | E | 20040915 | AT 1999-933522 | 19990618 |
| | US 2003130289 | A1 | 20030710 | US 2002-309535 | 20021203 |
| PRAI | US 1998-89978P | P | 19980619 | | |
| | US 1999-336098 | A3 | 19990618 | | |
| | WO 1999-US13809 | W | 19990618 | | |

OS MARPAT 132:64265

AB RZCR2R12CR3R13Z1R5 [I; R = (un)substituted (hetero)aryl; Z = O, NR1, CR1R11; Z1 = O, NR4, CR4R14; R1-R4 = H, OH, NH2, alkyl, alkoxy, etc.; R5 = (un)substituted 2-pyridyl or -pyrimidyl; R11-R14 = H or alkyl] were prepared Thus, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine which was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to give, after resin cleavage, title compound II. Data for biol. activity of I were given.

IT 252904-09-9P 252904-11-3P 252904-13-5P

252904-31-7P 252904-32-8P 252904-33-9P

252904-34-0P 252904-35-1P 252904-36-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)

RN 252904-09-9 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-[(5-nitro-2-


Give on 4/17

pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-11-3 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-13-5 CAPLUS

CN Benzamide, N-[(3-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 252904-31-7 CAPLUS

CN Benzamide, 4-[2-[[2-(2-pyridinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 252904-32-8 CAPLUS

CN Benzamide, 4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 252904-33-9 CAPLUS

CN Benzamide, 4-[2-[[2-[(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 252904-34-0 CAPLUS

CN Benzamide, 4-[2-[[3-(1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-35-1 CAPLUS


CN Benzanide, 4-[2-[[3-(2-naphthalenyloxy)propyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RN 252904-36-2 CAPLUS

CN Benzenepropanamide, α -[[4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]benzoyl]amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:723017 CAPLUS
 DN 131:337034
 TI Preparation of 1-naphthylsulfonyl-4-heteroarylbenzoylpiperazines and
 analogs as Factor Xa inhibitors
 IN Nowak, Thorsten; Preston, John; Rayner, John Wall; Smithers, Michael
 James; Stocker, Andrew
 PA Zeneca Limited, UK
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9957099 | A1 | 19991111 | WO 1999-GB1312 | 19990427 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9936207 | A1 | 19991123 | AU 1999-36207 | 19990427 |
| | EP 1082303 | A1 | 20010314 | EP 1999-918179 | 19990427 |
| | EP 1082303 | B1 | 20050126 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | AT 287874 | E | 20050215 | AT 1999-918179 | 19990427 |
| | US 6395731 | B1 | 20020528 | US 2000-674563 | 20001220 |
| PRAI | GB 1998-9349 | A | 19980502 | | |
| | WO 1999-GB1312 | W | 19990427 | | |

OS MARPAT 131:337034


AB Title compds. (I) [where A = 5- or 6-membered monocyclic heteroaryl
 (un)substituted by 1-3 halo, oxo, CO₂H, CF₃, CN, NH₂, OH, NO₂,
 (amino)alkyl, alkoxy(carbonyl), and/or (di)alkylamino; Y = (un)substituted
 phenylene; Z = (un)substituted piperidine-4,1-diyl or piperazine-1,4-diyl;
 D and D1 = independently H, alkyl, alkenyl, alkynyl, oxo, or OH; E = F,
 Cl, or Br] were prepared as antithrombotics and anticoagulants. Thus,
 4-(4-imidazolyl)benzoic acid HCl (2-step preparation given) was amidated with
 1-(6-chloronaphth-2-ylsulfonyl)piperazine to yield the title
 imidazolylbenzoylpiperazine (II). The IC₅₀ values of invention compds.
 ranged from 0.001 to 0.1 μ M for Factor Xa inhibition and were > 40
 μ M for thrombin inhibition (no individual data given). Data for
 anticoagulant activity of I in conventional prothrombin time tests were
 given.

IT 249887-66-9P 249887-68-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of 1-naphthylsulfonyl-4-
 heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors for
 treatment of thrombosis mediated diseases and coagulation disorders)


RN 249887-66-9 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[4-[2-[[2-
 (dimethylamino)ethyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 249887-68-1 CAPLUS

CN Glycine, N-[4-[4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:794998 CAPLUS
 DN 130:38404
 TI Preparation of 1-benzoyl-4-naphthalenesulfonylpiperazines and related compounds as inhibitors of activated coagulation factor X.
 IN Tawada, Hiroyuki; Ito, Fumio; Moriya, Norihiko; Terashita, Zenichi
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 313 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9854164 | A1 | 19981203 | WO 1998-JP2346 | 19980528 |
| | W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2287292 | AA | 19981203 | CA 1998-2287292 | 19980528 |
| | AU 9874534 | A1 | 19981230 | AU 1998-74534 | 19980528 |
| | EP 986551 | A1 | 20000322 | EP 1998-921852 | 19980528 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 11236372 | A2 | 19990831 | JP 1998-148677 | 19980529 |
| | US 6359134 | B1 | 20020319 | US 1999-424892 | 19991130 |
| PRAI | JP 1997-142250 | A | 19970530 | | |
| | JP 1997-351806 | A | 19971219 | | |
| | WO 1998-JP2346 | W | 19980528 | | |

OS MARPAT 130:38404

AB R1SO2ACOYXZ [R1 = (substituted) hydrocarbyl, heterocyclyl; A = (substituted) divalent N-heterocyclyl; Y = (substituted) hydrocarbylene, heterocyclylene; X = bond, (substituted) alkylene; Z = substituted amino, imidoyl, N-heterocyclyl; provided that when X = bond and Z = (substituted) 6-membered N-heterocyclyl, then Y = (substituted) hydrocarbylene, unsatd. heterocyclylene], were prepared Thus, reaction of 1-(6-chloronaphthalene-2-sulfonyl)piperazine hydrochloride with 2-(4-pyridyl)-4-methyl-5-thiazolecarboxylic acid in the presence of Et3N and WSC hydrochloride in DMF gave 1-(6-chloronaphthalene-2-sulfonyl)-4-[2-(4-pyridyl)-4-methyl-5-thiazolecarbonyl]piperazine. The latter inhibited human activated coagulation factor X with IC50 = 0.019 µM.


IT 216958-01-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-benzoyl-4-naphthalenesulfonylpiperazines and related compds. as inhibitors of activated coagulation factor X)

RN 216958-01-9 CAPLUS

CN Piperazine, 1-[4-(2-amino-4-pyrimidinyl)benzoyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




IT 216959-98-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 1-benzoyl-4-naphthalenesulfonylpiperazines and related
comps. as inhibitors of activated coagulation factor X)

RN 216959-98-7 CAPLUS

CN Benzoic acid, 4-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:457074 CAPLUS
 DN 127:81461
 TI Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors
 IN Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 PA Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9719065 | A1 | 19970529 | WO 1996-GB2854 | 19961120 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5958935 | A | 19990928 | US 1996-753041 | 19961119 |
| | AU 9676314 | A1 | 19970611 | AU 1996-76314 | 19961120 |
| | EP 862560 | A1 | 19980909 | EP 1996-939171 | 19961120 |
| | EP 862560 | B1 | 20030402 | | |
| | R: CH, DE, ES, FR, GB, IT, LI | | | | |
| | ES 2195020 | T3 | 20031201 | ES 1996-939171 | 19961120 |
| | US 6235746 | B1 | 20010522 | US 1999-249760 | 19990216 |
| PRAI | GB 1995-23675 | A | 19951120 | | |
| | US 1996-753041 | A3 | 19961119 | | |
| | WO 1996-GB2854 | W | 19961120 | | |

OS MARPAT 127:81461

AB The title compds. [I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom.


group], selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepared. Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4.H2O in EtOH afforded I.2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.

IT 191727-37-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors)


RN 191727-37-4 CAPLUS

CN Benzoic acid, 4-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:909361 CAPLUS
 DN 123:313996
 TI Preparation of N-phenyl-2-pyrimidineamine antitumor agents
 IN Zimmermann, Juerg
 PA Ciba-Geigy A.-G., Switz.
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9509847 | A1 | 19950413 | WO 1994-EP3150 | 19940921 |
| | W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN | | | | |
| | RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2148931 | AA | 19950413 | CA 1993-2148931 | 19930921 |
| | AU 9476976 | A1 | 19950501 | AU 1994-76976 | 19940921 |
| | AU 693475 | B2 | 19980702 | | |
| | EP 672035 | A1 | 19950920 | EP 1994-927634 | 19940921 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 08503971 | T2 | 19960430 | JP 1994-510577 | 19940921 |
| | US 5612340 | A | 19970318 | US 1995-436345 | 19950517 |
| PRAI | CH 1993-2967 | A | 19931001 | | |
| | CH 1994-2279 | A | 19940718 | | |
| | WO 1994-EP3150 | W | 19940921 | | |
| OS | MARPAT 123:313996 | | | | |
| AB | N-phenyl-2-pyrimidineamine derivs. [I; R1 = naphthyl, fluorenyl, anthracenyl, (un)substituted cyclic residue, etc.; R2 = NO2, F-substituted lower alkoxy, etc.] [e.g., N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine; m.p. 132°], useful for the treatment of tumor diseases (no data), are prepared and I-containing formulations presented. | | | | |
| IT | 170141-39-6P 170141-40-9P 170141-41-0P 170141-42-1P RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-phenyl-2-pyrimidineamine antitumor agents) | | | | |
| RN | 170141-39-6 CAPLUS | | | | |
| CN | Benzamide, 3-[2-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME) | | | | |




RN 170141-40-9 CAPLUS
 CN Benzamide, N-(2-aminoethyl)-3-[2-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 170141-41-0 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-3-[2-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 170141-42-1 CAPLUS

CN Benzoic acid, 3-[2-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1984:34487 CAPLUS
 DN 100:34487
 TI 2-Benzazepines. 7. Synthesis of pyrimido[5,4-d][2]benzazepines
 AU Earley, James V.; Fryer, R. Ian; Gilman, Norman W.
 CS Dep. Chem., Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA
 SO Journal of Heterocyclic Chemistry (1983), 20(5), 1195-7
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 100:34487
 AB Two novel syntheses of pyrimido[5,4-d][2]benzazepine I are described. The first synthesis started with 3-phenylphthalide which in 3 steps was converted to a functionalized pyrimidine II which was cyclized to give I. The second approach used o-benzoylbenzoic acid Me ester as the starting material, which in 4 steps was converted to II.
 IT **76988-36-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reductive cyclization of, pyrimidobenzazepine from)
 RN 76988-36-8 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-amino-4-(2-benzoylphenyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1981:139827 CAPLUS
 DN 94:139827
 TI Benzazepine derivatives, intermediates for their preparation, their use
 and pharmaceutical compositions containing them
 IN Fryer, Rodney Ian; Gilman, Norman W.; Trybulski, Eugene J.; Walser, Armin
 PA Hoffmann-La Roche, F., und Co. A.-G., Switz.
 SO Eur. Pat. Appl., 92 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------------------------------|------|----------|-----------------|----------|
| PI | EP 14470 | A2 | 19800820 | EP 1980-100610 | 19800206 |
| | EP 14470 | A3 | 19820210 | | |
| | EP 14470 | B1 | 19850710 | | |
| | R: AT, BE, CH, DE, FR, IT, LU, NL, SE | | | | |
| | AT 13420 | E | 19850615 | AT 1982-100359 | 19800204 |
| | DK 8000498 | A | 19800808 | DK 1980-498 | 19800205 |
| | NL 8000715 | A | 19800811 | NL 1980-715 | 19800205 |
| | FR 2450833 | A1 | 19801003 | FR 1980-2469 | 19800205 |
| | FR 2450833 | B1 | 19830610 | | |
| | CA 1138863 | A1 | 19830104 | CA 1980-345062 | 19800205 |
| | IL 59316 | A1 | 19830731 | IL 1980-59316 | 19800205 |
| | SU 1181547 | A3 | 19850923 | SU 1980-2879255 | 19800205 |
| | FI 8000367 | A | 19800808 | FI 1980-367 | 19800206 |
| | FI 68832 | B | 19850731 | | |
| | FI 68832 | C | 19851111 | | |
| | NO 8000316 | A | 19800808 | NO 1980-316 | 19800206 |
| | NO 153138 | B | 19851014 | | |
| | NO 153138 | C | 19860122 | | |
| | SE 8000964 | A | 19800808 | SE 1980-964 | 19800206 |
| | AU 8055296 | A1 | 19800814 | AU 1980-55296 | 19800206 |
| | AU 535233 | B2 | 19840308 | | |
| | DE 3004381 | A1 | 19800904 | DE 1980-3004381 | 19800206 |
| | JP 55122782 | A2 | 19800920 | JP 1980-12578 | 19800206 |
| | JP 59007715 | B4 | 19840220 | | |
| | GB 2043636 | A | 19801008 | GB 1980-3910 | 19800206 |
| | GB 2043636 | B2 | 19830511 | | |
| | BR 8000737 | A | 19801021 | BR 1980-737 | 19800206 |
| | ES 488311 | A1 | 19801216 | ES 1980-488311 | 19800206 |
| | DD 149066 | C | 19810624 | DD 1980-218921 | 19800206 |
| | IN 151574 | A | 19830528 | IN 1980-CA138 | 19800206 |
| | HU 25090 | O | 19830530 | HU 1980-271 | 19800206 |
| | HU 182662 | B | 19840228 | | |
| | AT 14225 | E | 19850715 | AT 1980-100610 | 19800206 |
| | CS 241471 | B2 | 19860313 | CS 1980-799 | 19800206 |
| | RO 79168 | P | 19820625 | RO 1980-100118 | 19800207 |
| | PL 125349 | B1 | 19830430 | PL 1980-230173 | 19800207 |
| | ES 495078 | A1 | 19810701 | ES 1980-495078 | 19800916 |
| | ES 495077 | A1 | 19811001 | ES 1980-495077 | 19800916 |
| | ES 495079 | A1 | 19811001 | ES 1980-495079 | 19800916 |
| | ES 495080 | A1 | 19811016 | ES 1980-495080 | 19800916 |
| | US 4481142 | A | 19841106 | US 1982-437047 | 19821027 |
| | US 4546183 | A | 19851008 | US 1984-643509 | 19840823 |
| | US 4547581 | A | 19851015 | US 1984-643563 | 19840823 |
| PRAI | US 1979-10118 | A | 19790207 | | |

US 1979-16709 A 19790301
 CH 1980-510 A 19800122
 CH 1980-511 A 19800122
 EP 1982-100359 A 19800204
 EP 1980-100610 A 19800206
 US 1980-151025 A1 19800519
 US 1982-437047 A3 19821027
 OS CASREACT 94:139827
 AB Pyrimido[5,4-d][2]benzazepines I [R = H, R1 = H or alkyl, or RR1 = bond;
 R2 = H, Br, Cl, OH, SH, alkoxy, alkylthio, (alkylated) amino, or CH2COR6,
 where R6 = H, alkoxy, or (alkylated) amino; R3 = H, NH2 or dialkylamino;
 R4 = H, OH or acyloxy; R5 = H, halo, CF3, Et, HOCHMe, or MeCO; X = H or
 halo; m, n = 0 or 1, the latter only when RR1 = bond], which showed
 sedative activity in tests on cats and mice, were prepared Thus,
 cyclocondensation of 8-chloro-1-(2-chlorophenyl)-3,4-dihydro-4-
 [(dimethylamino)methylene]-5H-2-benzazepin-2-one with MeC(:NH)NH2.HCl gave
 I (RR1 = bond, R2 = Me, R3 = R4 = H, R5 = X = Cl, m = n = 0).
 IT **76988-32-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrogenation of)
 RN 76988-32-4 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-amino-4-[4-chloro-2-(2-fluorobenzoyl)phenyl]-
 (9CI) (CA INDEX NAME)



IT **76988-36-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrogenation-cyclocondensation of)
 RN 76988-36-8 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-amino-4-(2-benzoylphenyl)- (9CI) (CA INDEX
 NAME)



L8 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1974:70833 CAPLUS
 DN 80:70833
 TI 2,4-Bis(o-carboxyanilino)pyrimidines or their salts
 IN Fadeicheva, A. G.; Karp, V. K.; Portnyagina, V. A.; Trinus, F. P.;
 Mokhort, N. A.; Faktorovich, I. L.; Barkova, I. S.
 PA Kiev Scientific-Research Institute of Pharmacology and Toxicology
 SO U.S.S.R.
 From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1973, 50(36),
 44.


CODEN: URXXAF

DT Patent



LA Russian

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | SU 396334 | T | 19730829 | SU 1971-1681393 | 19710708 |
| PRAI | SU 1971-1681393 | A | 19710708 | | |
| AB | The pyrimidines I (R = H, alkyl, halo, CO ₂ H; R ₁ = H, alkyl, halo, NO ₂) were prepared by the reaction of the corresponding 2,4-dichloropyrimidine with o-H ₂ NC ₆ H ₄ CO ₂ H in an organic solvent, e.g., DMF or AcOH, at 100-10°. | | | | |
| IT | 51126-66-0DP, Benzoic acid, 2-[2-[(2-carboxyphenyl)amino]-4-pyrimidinyl]-, derivative | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of) | | | | |
| RN | 51126-66-0 CAPLUS | | | | |
| CN | Benzoic acid, 2-[2-[(2-carboxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME) | | | | |



L8 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1962:74764 CAPLUS
 DN 56:74764
 OREF 56:14588b-c
 TI Radiation prophylaxis by some new purines and pyrimidines
 AU Krasnykh, I. G.; Shashkov, V. S.; Magidson, O. Yu.; Golovchinskaya, E. S.;
 Chkhikvadze, K. A.
 SO Farmakologiya i Toksikologiya (Moscow) (1961), 24, 572-7
 CODEN: FATOAO; ISSN: 0014-8318
 DT Journal
 LA Unavailable
 AB Mice were given intraperitoneal or subcutaneous injections, 10-15 min.
 prior to exposure to 700 r. (x-rays), of 4 uracils, 3 caffeine derivs., a
 theobromine derivative, and 12 pyrimidines. Up to 20% protection against
 radiation damage was given by compds. containing aminoethyl or aminomethyl
 groups, as against 50-60% protection with mercamine. Some compds. caused
 hypothermia, in no apparent relation to protective effect. Some drugs
 were given as the free base, others as hydrohalides. Doses and results
 are tabulated.
 IT 95770-36-8, Benzoic acid, o-(2-amino-4-pyrimidinyl)-, ethyl ester,
 hydrochloride
 (in radiation-damage prevention)
 RN 95770-36-8 CAPLUS
 CN Benzoic acid, o-(2-amino-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI)
 (CA INDEX NAME)



● HCl

=> => d his

(FILE 'HOME' ENTERED AT 19:41:04 ON 11 DEC 2005)

FILE 'REGISTRY' ENTERED AT 19:41:11 ON 11 DEC 2005

L1 STRUCTURE UPLOADED
 L2 50 S L1 SSS SAM
 L3 STRUCTURE UPLOADED
 L4 50 S L3 SSS SAM
 L5 STRUCTURE UPLOADED
 L6 27 S L5 SSS SAM
 L7 446 S L5 SSS FUL

FILE 'CAPLUS' ENTERED AT 19:45:07 ON 11 DEC 2005

L8 29 S L7



FILE 'CAOLD' ENTERED AT 19:46:16 ON 11 DEC 2005

=> s 17

L9 1 L7

=> d 19 bib,hitstr

L9 ANSWER 1 OF 1 CAOLD COPYRIGHT 2005 ACS on STN
AN CA56:14588b CAOLD
TI radiation prophylaxis by purines and pyrimidines
AU Krasnykh, I. G.; Shashkov, V. S.; Magidson, O. Yu.; Golovchinskaya, E. S.;
Chkhikvadze, K. A.
IT 95770-36-8
RN 95770-36-8 CAOLD
CN Benzoic acid, o-(2-amino-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI)
(CA INDEX NAME)



● HCl

10/639,784

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.26

311.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-21.17

STN INTERNATIONAL LOGOFF AT 19:46:38 ON 11 DEC 2005

Application
Number

SEARCH

IDS Flag Clearance for Application 10700333



| Content | Mailroom Date | Entry Number | IDS Review | Reviewer |
|---------|---------------|-----------------|-------------------------------------|------------------------------|
| M844 | 04-06-2004 | 16 | <input checked="" type="checkbox"/> | 08-11-2005 00:50:32 IDS CONV |

UPDATE